CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority under 35 U.S.C. § 119(e) of U.S.

Provisional Application Serial Number 62/758,474, filed November 9, 2018, entitled

“Biosynthesis of Mogrosides,” the disclosure of which is incorporated by reference here in its entirety.

REFERENCE TO A SEQUENCE LISTING SUBMITTED AS A TEXT FILE VIA EFS-WEB The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on November 9, 2019, is named G09l970023WO00-SEQ-OMJ.TXT and is 928 kilobytes in size.

FIELD OF THE INVENTION

The present disclosure relates to the production of mogrol precursors, mogrol and mogrosides in recombinant cells.

BACKGROUND

Mogrosides are glycosides of cucurbitane derivatives. Highly sought after as sweeteners and sugar alternatives, mogrosides are naturally synthesized in the fruits of plants, including Siraitia grosvenorii ( S . grosvenorii). Although anti-cancer, anti-oxidative, and anti

inflammatory properties have been ascribed to mogrosides, characterization of the exact enzymes involved in mogroside biosynthesis is limited. Furthermore, mogroside extraction from fruit is labor-intensive and the structural complexity of mogrosides often hinders de novo chemical synthesis.

SUMMARY

Aspects of the invention relate to a host cell that comprises a heterologous polynucleotide encoding a UDP-glycosyltransferase (UGT), wherein the UGT comprises a region that: corresponds to residues 83 to 92 of wild-type UGT94-289-1 (SEQ ID NO: 109), wherein the region comprises an amino acid substitution relative to residues 83 to 92 of wild-type UGT94- 289-1 (SEQ ID NO: 109); and/or corresponds to residues 179 to 198 of wild-type UGT94-289-1 (SEQ ID NO: 109), wherein the region comprises an amino acid substitution relative to residues 179 to 198 of wild-type UGT94-289-1 (SEQ ID NO: 109); wherein the host cell produces in the presence of at least one mogroside precursor at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more of one or more mogrosides relative to a control host cell that comprises a heterologous polynucleotide encoding wild-type UGT94-289-1 (SEQ ID NO: 109).

In some embodiments, the UGT exhibits at least a 1.3-fold increase in activity (e.g., specific activity) relative to wildtype UGT94-289-1 (SEQ ID NO: 109). In some embodiments, the UGT comprises an amino acid substitution at an amino acid residue located in a structural motif corresponding to a structural motif in wild-type UGT94-289-1 (SEQ ID NO: 109) selected from: loop 6, alpha helix 3, loop 11, alpha helix 6, loop 12, and alpha helix 7. In some embodiments, the UGT is capable of catalyzing conversion of: Mogrol to MIA1; Mogrol to MIE1; MIA1 to MIIA1; MIE1 to MIIE; MIIA1 to MIIIA1; MIA1 to MIIE; MIIA1 to Mill; MIIIA1 to siamenoside I; MIIE to Mill; Mill to siamenoside I; MIIE to MIIIE; and/or MIIIE to siamenoside I. In some embodiments, the UGT is capable of: glycosylation of mogrol at C24; glycosylation of mogroside at C3; branching glycosylation of mogroside at C3; or branching glycosylation of mogroside C24. In some embodiments, the UGT comprises an amino acid substitution at an amino acid residue corresponding to the amino acid residue in wild-type UGT94-289-1 (SEQ ID NO: 109) selected from: H83; T84; T85; N86; P89; L92; Y179; S180; A181; G184; A185; V186; T187; K189; H191; K192; G194; E195; and A198. In some embodiments, the host cell further comprises a heterologous polynucleotide encoding a cucurbitadienol synthase (CDS) enzyme.

Further aspects of the invention relate to a host cell that comprises a heterologous polynucleotide encoding a UGT, wherein the UGT comprises a region that: corresponds to residues 83 to 92 of wild-type UGT94-289-1 (SEQ ID NO: 109), wherein the region comprises an amino acid substitution relative to residues 83 to 92 of wild-type UGT94-289-1 (SEQ ID NO: 109); and/or corresponds to residues 179 to 198 of wild-type UGT94-289-1 (SEQ ID NO: 109) wherein the region comprises an amino acid substitution relative to residues 179 to 198 of wild- type UGT94-289-1 (SEQ ID NO: 109); wherein the UGT comprises less than 90% identity to SEQ ID NO: 109.

In some embodiments, the UGT exhibits at least a 1.3-fold increase in activity ( e.g ., specific activity) relative to wildtype UGT94-289-1 (SEQ ID NO: 109). In some embodiments, the UGT comprises an amino acid substitution at an amino acid residue located in a structural motif corresponding to a structural motif in wild-type UGT94-289-1 (SEQ ID NO: 109) selected from: loop 6, alpha helix 3, loop 11, alpha helix 6, loop 12, and alpha helix 7. In some embodiments, the UGT is capable of catalyzing conversion of: Mogrol to MIA1; Mogrol to MIE1; MIA1 to MIIA1; MIE1 to MIIE; MIIA1 to MIIIA1; MIA1 to MIIE; MIIA1 to Mill; MIIIA1 to siamenoside I; MIIE to Mill; Mill to siamenoside I; MIIE to MIIIE; and/or MIIIE to siamenoside I. In some embodiments, the UGT is capable of: glycosylation of mogrol at C24; glycosylation of mogroside at C3; branching glycosylation of mogroside at C3; or branching glycosylation of mogroside C24. In some embodiments, the host cell further comprises a heterologous polynucleotide encoding a CDS enzyme.

Further aspects of the invention relate to a host cell that comprises a heterologous polynucleotide encoding a UGT, wherein the UGT comprises an amino acid substitution at a residue corresponding to N143 or L374 of wild-type UGT94-289-1 (SEQ ID NO: 109), wherein the host cell produces in the presence of at least one mogroside precursor at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more of one or more mogrosides relative to a host cell that comprises a heterologous polynucleotide encoding wild-type UGT94-289-1 (SEQ ID NO: 109).

In some embodiments, the UGT exhibits at least a 1.3-fold increase in activity (e.g., specific activity) relative to wildtype UGT94-289-1 (SEQ ID NO: 109). In some embodiments, the UGT comprises an amino acid substitution at an amino acid residue located in a structural motif of the UGT corresponding to a structural motif in wild-type UGT94-289-1 (SEQ ID NO: 109) selected from: loop 6, alpha helix 3, loop 11, alpha helix 6, loop 12, and alpha helix 7. In some embodiments, the UGT is capable of catalyzing conversion of: Mogrol to MIA1; Mogrol to MIE1; MIA1 to MIIA1; MIE1 to MIIE; MIIA1 to MIIIA1; MIA1 to MIIE; MIIA1 to Mill; MIIIA1 to siamenoside I; MIIE to Mill; Mill to siamenoside I; MIIE to MIIIE; and/or MIIIE to siamenoside I. In some embodiments, the UGT is capable of: glycosylation of mogrol at C24; glycosylation of mogroside at C3; branching glycosylation of mogroside at C3; or branching glycosylation of mogroside C24. In some embodiments, the host cell further comprises a heterologous polynucleotide encoding a CDS enzyme.

Further aspects of the invention relate to a host cell that comprises a heterologous polynucleotide encoding a UGT, wherein the UGT comprises an amino acid substitution at an amino acid residue located in a structural motif corresponding to a structural motif of wild-type UGT94-289-1 (SEQ ID NO: 109) selected from: loop 8; beta sheet 5; loop 10; alpha helix 5; loop 11; loop 2; alpha helix 6; loop 12; alpha helix 1; alpha helix 7; loop 18; alpha helix 14; loop 26; alpha helix 2; loop 6; and alpha helix 3; wherein the host cell produces in the presence of at least one mogroside precursor at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more of one or more mogrosides relative to a host cell that comprises a heterologous polynucleotide encoding a UGT that does not comprise the amino acid substitution.

In some embodiments, the UGT exhibits at least a 1.3-fold increase in activity ( e.g ., specific activity) relative to wildtype UGT94-289-1 (SEQ ID NO: 109). In some embodiments, the UGT is capable of catalyzing conversion of: Mogrol to MIA1; Mogrol to MIE1; MIA1 to MIIA1; MIE1 to MIIE; MIIA1 to MIIIA1; MIA1 to MIIE; MIIA1 to Mill; MIIIA1 to siamenoside I; MIIE to Mill; Mill to siamenoside I; MIIE to MIIIE; and/or MIIIE to

siamenoside I. In some embodiments, the UGT is capable of: glycosylation of mogrol at C24; glycosylation of mogroside at C3; branching glycosylation of mogroside at C3; or branching glycosylation of mogroside C24. In some embodiments, the host cell further comprises a heterologous polynucleotide encoding a CDS enzyme.

Further aspects of the invention relate to a host cell that comprises a heterologous polynucleotide encoding a UGT, wherein the UGT comprises an amino acid substitution at an amino acid residue that is within 7 angstrom of a catalytic dyad corresponding to H21/D122 of wildtype UGT94-289-1 (SEQ ID NO: 109), wherein the UGT exhibits at least a 1.3-fold increase in activity (e.g., specific activity) relative to the same UGT not comprising the amino acid substitution.

Further aspects of the invention relate to host cells that comprises a heterologous polynucleotide encoding a circularly permutated UDP-glycosyltransferase (UGT), wherein the circularly permutated UGT comprises: (a) a catalytic dyad; and (b) a cofactor binding site;

wherein the catalytic dyad is located C-terminal to the cofactor-binding site, and wherein the host cell produces in the presence of at least one mogroside precursor at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more of one or more mogrosides relative to a control host cell that comprises a heterologous polynucleotide encoding wild-type UGT94- 289-1 (SEQ ID NO: 109).

In some embodiments, a circularly permutated UGT comprises a sequence that is at least 90% identical to a sequence within Table 6.

In some embodiments, a UGT described in this application comprises a sequence that is at least 90% identical to a sequence within Table 3 or Table 7.

In some embodiments, the UGT comprises an amino acid substitution at an amino acid residue located in a structural motif corresponding to a structural motif in wild-type UGT94-289- 1 (SEQ ID NO: 109) selected from: loop 6, alpha helix 3, loop 11, alpha helix 6, loop 12, and alpha helix 7.

In some embodiments, the UGT exhibits at least a 1.3-fold increase in activity ( e.g ., specific activity) relative to wildtype UGT94-289-1 (SEQ ID NO: 109). In some embodiments, the host cell produces in the presence of at least one mogroside precursor at least 40%, 50%, 60%, 70%, 80%, 90%, or 100% more of one or more mogrosides relative to a host cell that comprises a heterologous polynucleotide encoding a UGT that does not comprise the amino acid substitution.

In some embodiments, the UGT is capable of catalyzing conversion of: Mogrol to MIA1; Mogrol to MIE1; MIA1 to MIIA1; MIE1 to MIIE; MIIA1 to MIIIA1; MIA1 to MIIE; MIIA1 to Mill; MIIIA1 to siamenoside I; MIIE to Mill; Mill to siamenoside I; MIIE to MIIIE; and/or MIIIE to siamenoside I. In some embodiments, the UGT is capable of: glycosylation of mogrol at C24; glycosylation of mogroside at C3; branching glycosylation of mogroside at C3; or branching glycosylation of mogroside C24. In some embodiments, the host cell further comprises a heterologous polynucleotide encoding a CDS enzyme.

In some embodiments, the specific activity of the UGT is at least 1 mmol glycosylated mogroside target produced per gram of enzyme per hour.

Further aspects of the invention relate to a host cell that comprises a heterologous polynucleotide encoding a UGT, wherein the UGT comprises an amino acid substitution at an amino acid residue corresponding to the amino acid residue in wild-type UGT94-289-1 (SEQ ID NO: 109) selected from: H83; T84; T85; N86; P89; L92; Y179; S180; A181; G184; A185;

V186; T187; K189; H191; K192; G194; E195; and A198.

Further aspects of the invention relate to a host cell that comprises a heterologous polynucleotide encoding a UGT, wherein the UGT comprises an amino acid substitution at an amino acid residue corresponding to the amino acid residue in wild-type UGT94-289-1 (SEQ ID NO: 109) selected from: G18; Y19; S123; N47; F124; N143, T144; T145; V149; F276; N355; H373 and L374.

In some embodiments, the UGT is capable of catalyzing conversion of: Mogrol to MIA1; Mogrol to MIE1; MIA1 to MIIA1; MIE1 to MIIE; MIIA1 to MIIIA1; MIA1 to MIIE; MIIA1 to Mill; MIIIA1 to siamenoside I; MIIE to Mill; Mill to siamenoside I; MIIE to MIIIE; and/or MIIIE to siamenoside I. In some embodiments, the UGT is capable of: glycosylation of mogrol at C24; glycosylation of mogroside at C3; branching glycosylation of mogroside at C3; or branching glycosylation of mogroside C24. In some embodiments, the UGT exhibits at least a 1.3-fold increase in activity ( e.g ., specific activity) relative to wildtype UGT94-289-1 (SEQ ID NO: 109). In some embodiments, the host cell produces in the presence of at least one mogroside precursor at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more of one or more mogrosides relative to a host cell that comprises a heterologous polynucleotide encoding wild-type UGT94-289-1 (SEQ ID NO: 109).

In some embodiments, Y179 is mutated to glutamate, phenylalanine, histidine, isoleucine, lysine, leucine, valine, or tryptophan; S 180 is mutated to alanine or valine; A 181 is mutated to lysine or threonine; G 184 is mutated to alanine, cysteine, aspartate, glutamate, phenylalanine, histidine, isoleucine, lysine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, or tyrosine; A185 is mutated to cysteine, aspartate, glutamate, glycine, lysine, leucine, methionine, asparagine, proline, glutamine, threonine, tryptophan or tyrosine; VI 86 is mutated to alanine, cysteine, aspartate, glutamate, glycine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, threonine, tryptophan, or tyrosine; T187 is mutated to alanine, cysteine, aspartate, glutamate, glycine, histidine, isoleucine, lysine, leucine, asparagine, proline, arginine, serine, valine, tryptophan, or tyrosine; K189 is mutated to alanine, cysteine, aspartate, glutamate, phenylalanine, glycine, histidine, isoleucine, leucine, methionine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine; H191 is mutated to alanine, cysteine, aspartate, glutamate, glycine, lysine, methionine, proline, glutamine, serine, threonine, valine, tryptophan, or tyrosine; K192 is mutated to cysteine or phenylalanine; G194 is mutated to aspartate, leucine, methionine, asparagine, proline, serine, or tryptophan; El 95 is mutated to alanine, isoleucine, lysine, leucine, asparagine, glutamine, serine, threonine, or tyrosine; A 198 is mutated to cysteine, aspartate, glutamate, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, or tyrosine; H83 is mutated to glutamine or tryptophan; T84 is mutated to tyrosine; T85 is mutated to glycine, lysine, proline, serine, or tyrosine; N86 is mutated to alanine, cysteine, glutamate, isoleucine, lysine, leucine, serine, tryptophan, or tyrosine; P89 is mutated to methionine or serine; and/or L92 is mutated to histidine or lysine.

In some embodiments, N143 is mutated to alanine, cysteine, glutamate, isoleucine, leucine, methionine, glutamine, serine, threonine or valine; L374 is mutated to alanine, cysteine, phenylalanine, histidine, methionine, asparagine, glutamine, serine, threonine, valine, tryptophan, or tyrosine; S123 is mutated to alanine, cysteine, glycine or valine; F124 is mutated to tyrosine; T144 is mutated to alanine, cysteine, asparagine or proline; T145 is mutated to alanine, cysteine, glycine, methionine, asparagine, glutamine, or serine; V149 is mutated to cysteine, leucine or methionine; G18 is mutated to serine; Y19 is mutated to phenylalanine, histidine, leucine, or valine; F276 is mutated to cysteine or glutamine; N355 is mutated to glutamine or serine; H373 is mutated to lysine, leucine, methionine, arginine, valine, or tyrosine; and/or N47 is mutated to glycine.

In some embodiments, the host cell further comprises a heterologous polynucleotide encoding a CDS enzyme, a Cl l hydroxylase, a cytochrome P450 reductase, an epoxide hydrolase (EPH), and/or a squalene epoxidase. In some embodiments, the heterologous polynucleotide encoding the CDS is at least 90% identical to SEQ ID NOs: 3, 9, or 12. In some embodiments, the CDS is at least 90% identical to SEQ ID NOs: 43, 49, or 52.

In some embodiments, the activity ( e.g ., specific activity) of the UGT is at least 1 mmol glycosylated mogroside target produced per gram of enzyme per hour. In some embodiments, the cell is a yeast cell, a plant cell, or a bacterial cell. In some embodiments, the cell is a

Saccharomyces cerevisiae ( S . cerevisiae ) cell. In some embodiments, the cell is an Escherichia coli (E. coli) cell.

Further aspects of the invention relate to methods of producing a mogroside comprising culturing any of the host cells described in this application with at least one mogroside precursor. In some embodiments, the mogroside precursor is selected from mogrol, MIA1, MIIA1, MIIIA1, MIIE, Mill, and MIIIE. In some embodiments, the mogroside that is produced is selected from MIA1, MIIA1, MIIIA1, MIIE, Mill, siamenoside, and MIIIE.

Further aspects of the invention relate to a host cell that comprises a heterologous polynucleotide encoding a CDS enzyme, wherein the CDS enzyme comprises an amino acid sequence that is at least 90% identical to a sequence selected from the sequences within Table 2 and wherein the host cell produces at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more cucurbitadienol compound compared to the same host cell that does not express the heterologous gene.

In some embodiments, the cucurbitadienol compound is 24-25 epoxy-cucurbitadienol or cucurbitadienol. In some embodiments, the CDS enzyme comprises a leucine at the amino acid residue corresponding to the amino acid residue at position 123 of SEQ ID NO: 73. In some embodiments, the CDS is capable of converting an oxidosqualene to the cucurbitadienol compound. In some embodiments, the oxidosqualene is 2-3-oxidosqualene or 2,3; 22,23- diepoxysqualene. In some embodiments, the CDS enzyme comprises a substrate channel and an active-site cavity.

In some embodiments, the host cell further expresses a heterologous gene encoding a Cl 1 hydroxylase enzyme, a cytochrome P450 reductase enzyme, an epoxide hydrolase (EPH) enzyme, and/or a squalene epoxidase enzyme.

Further aspects of the invention relate to a method of producing a cucurbitadienol compound, comprising contacting a host cell described in this application with an oxidosqualene, thereby producing the cucurbitadienol compound. In some embodiments, the cucurbitadienol compound is 24-25 epoxy-cucurbitadienol or cucurbitadienol. In some embodiments, the oxidosqualene is 2-3-oxidosqualene or 2,3; 22,23-diepoxysqualene. In some embodiments, the method further comprises isolating the cucurbitadienol compound.

Further aspects of the invention relate to a method of producing mogrol or a mogroside, comprising contacting a host cell described in this application with an oxidosqualene, thereby producing the mogrol or mogroside. Further aspects of the invention relate to a method of producing a mogroside comprising culturing a host cell described in this application with at least one mogroside precursor. Further aspects of the invention relate to host cells that comprise a heterologous polynucleotide encoding a cucurbitadienol synthase (CDS) enzyme, wherein the CDS comprises: a) the motif GXiWASDLGGP (SEQ ID NO: 331), wherein Xi is N or H; b) the motif DXiGWL (SEQ ID NO: 332), wherein Xi is H or Q; and/or c) the motif CWGVCFTYAGW (SEQ ID NO: 333), wherein the CDS does not comprise the sequence of S. grosvenorii CDS (SEQ ID NO: 73); and wherein the host cell produces at least 10%, 20%, or 30% more cucurbitadienol compound relative to a control, wherein the control is a host cell that expresses S. grosvenorii CDS, encoded by a polynucleotide corresponding to SEQ ID NO:33.

In some embodiments, the motif GXiWASDLGGP (SEQ ID NO: 331) is located at residues in the CDS corresponding to residues 117-126 in SEQ ID NO: 73; the motif DXiGWL (SEQ ID NO: 332) is located at residues in the CDS corresponding to residues 479-483 in SEQ ID NO: 73, and/or the motif CWGVCFTYAGW (SEQ ID NO: 333) is located at residues in the CDS corresponding to residues 612-622 in SEQ ID NO: 73.

Further aspects of the invention relate to host cells that comprises a heterologous polynucleotide encoding a cucurbitadienol synthase (CDS) enzyme, wherein the CDS comprises: a) the motif GHW AS DLGGP (SEQ ID NO: 334); and/or b) the motif DQGWL (SEQ ID NO: 335).

In some embodiments, the motif GHWASDLGGP (SEQ ID NO: 334) is located at residues in the CDS corresponding to residues 117-126 in SEQ ID NO: 73; and/or the motif DQGWL (SEQ ID NO: 335) is located at residues in the CDS corresponding to residues 479-483 in SEQ ID NO: 73.

Further aspects of the invention relate to host cells that comprise a heterologous polynucleotide encoding a cucurbitadienol synthase (CDS) enzyme, wherein the CDS comprises: a) the motif GHW ANDLGGP (SEQ ID NO: 336); b) the motif DQGWL (SEQ ID NO: 335); and/or c) the motif CWGVCYTYAGW (SEQ ID NO: 337).

In some embodiments, the motif GHW ANDLGGP (SEQ ID NO: 336) is located at residues in the CDS corresponding to residues 117-126 in SEQ ID NO: 73; the motif DQGWL (SEQ ID NO: 335) is located at residues in the CDS corresponding to residues 479-483 in SEQ ID NO: 73; and/or the motif CWGVCYTYAGW (SEQ ID NO: 337) is located at residues in the CDS corresponding to residues 612-622 in SEQ ID NO: 73. In some embodiments, the heterologous polynucleotide is at least 90% identical to SEQ ID NOs: 3, 9, or 12. In some embodiments, the CDS is at least 90% identical to SEQ ID NOs: 43, 49, or 52. In some embodiments, the heterologous polynucleotide is at least 90% identical to SEQ ID NO: 3. In some embodiments, the CDS is at least 90% identical to SEQ ID NOs: 43.

Further aspects of the invention relate to host cells that comprise a heterologous polynucleotide encoding a cucurbitadienol synthase (CDS) enzyme, wherein the heterologous polynucleotide sequence is at least 90% identical to SEQ ID NO: 3 and/or the amino acid sequence of the CDS encoded by the heterologous polynucleotide is at least 90% identical to SEQ ID NO: 43, and wherein the host cell produces a cucurbitadienol compound.

In some embodiments, the cucurbitadienol compound is 24-25 epoxy-cucurbitadienol or cucurbitadienol. In some embodiments, the CDS comprises a leucine at the amino acid residue corresponding to the amino acid residue at position 123 of SEQ ID NO: 73. In some

embodiments, the CDS is capable of converting an oxidosqualene to the cucurbitadienol compound. In some embodiments, the oxidosqualene is 2-3-oxidosqualene or 2,3; 22,23- diepoxysqualene. In some embodiments, the CDS enzyme comprises a substrate channel and an active-site cavity.

In some embodiments, the host cell further comprises aone or more heterologous polynucleotides encoding a UDP-glycosyltransferase (UGT), a Cl l hydroxylase, a cytochrome P450 reductase, an epoxide hydrolase (EPH), and/or a squalene epoxidase.

Further aspects of the invention relate to methods of producing a cucurbitadienol compound, comprising contacting any of the host cells described in this application with an oxidosqualene, thereby producing the cucurbitadienol compound. In some embodiments, the cucurbitadienol compound is 24-25 epoxy-cucurbitadienol or cucurbitadienol. In some embodiments, the oxidosqualene is 2-3-oxidosqualene or 2,3; 22,23-diepoxysqualene. In some embodiments, the method further comprises isolating the cucurbitadienol compound. In some embodiments, the host cell is a yeast cell, a plant cell, or a bacterial cell. In some embodiments, the host cell is a Saccharomyces cerevisiae cell. In some embodiments, the host cell is an E. coli cell.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention. This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways.

BRIEF DESCRIPTION OF DRAWINGS

The accompanying drawings are not intended to be drawn to scale. The drawings are illustrative only and are not required for enablement of the disclosure. For purposes of clarity, not every component may be labeled in every drawing. In the drawings:

FIGs. 1A-1D include schematic overviews of putative mogrol biosynthesis pathways. SQS indicates squalene synthase, EPD indicates epoxidase, P450 indicates Cl l hydroxylase, EPH indicates epoxide hydrolase, and CDS indicates cucurbitadienol synthase. FIG. 1A and FIG. 1B show putative mogrol biosynthesis pathways. FIG. 1C shows non-limiting examples of primary UGT activity. FIG. 1D shows non-limiting examples of secondary UGT activity.

FIG. 2 is a graph showing liquid chromatography-mass spectrometry (FC-MS) profiles of mogrol, mogroside I-Al, mogroside I-El, mogroside II-A1, mogroside II- A2, mogroside II-E, mogroside III-A1, mogroside III-E, mogroside IV, and siamenoside I. An 8 minute FC-MS method was used to distinguish between all these mogroside standards.

FIGs. 3A-3B include a series of graphs showing production of mogroside I-Al (FIG. 3A) and siamenoside I (FIG. 3B) from a UGT library screened against mogroside substrates. Two biological replicates of each strain were screened.

FIGs. 4A-4B include a series of graphs showing production of mogroside I-Al from mogrol (FIG. 4A) and siamenoside I from mogroside III-A1 (FIG. 4B) in a secondary screen of hit strains on individual substrates. Two biological replicates with two technical replicates of each were screened for each hit strain.

FIG. 5 is a schematic of a homology model of UGT94-289-1. Catalytic dyad side chains are shown within a box, and positions featuring activity enhancing mutations are highlighted in black.

FIG. 6 is a diagram showing the proximity of the N and C termini of the UGT94-289-1 homology model. FIG. 7 is a schematic showing circular permutation of a protein. The original N and C termini of the native protein are linked together, either directly or with a linker sequence. New N and C termini are introduced at another position within the protein sequence to produce sequence/structural variants.

FIG. 8 depicts diagrams showing Position-Specific Scoring Matrix (PSSM) of residues 50-59 of t85024_Nl43V (top panel) and evaluation of the impact of these potential mutations using the Rosetta energy function (bottom panel). In the bottom panel, the mutated residue is shown as sticks and the surrounding atoms are shown as lines.

FIG. 9 is a schematic depicting a non-limiting example of an alignment between the UGT U73C6 (SEQ ID NO: 103) and UGT94-289-1 (SEQ ID NO: 109). Boxes highlight residues in U73C6 (SEQ ID NO: 103) corresponding to positions 123, 143, and 273 in UGT94- 289-1 (SEQ ID NO: 109).

FIG. 10 is a graph showing relative production of M, MI, and Mil as compared to Mill, MIV, and MV by UGTs generated by circular permutation.

FIG. 11 is a graph showing relative production of M, MI, and Mil as compared to Mill, MIV, and MV by putative UGTs.

DETAILED DESCRIPTION

Mogrosides are widely used as natural sweeteners, for example in beverages. However, de novo synthesis and mogroside extraction from natural sources often involves high production costs and low yield. This application describes host cells that are engineered to efficiently produce mogrol (or 11, 24, 25-trihydroxy cucurbitadienol), mogrosides, and precursors thereof. Methods include heterologous expression of cucurbitadienol synthase (CDS) enzymes, UDP- glycosyltransferase (UGT) enzymes, Cl l hydroxylase enzymes, cytochrome P450 reductase enzymes, epoxide hydrolase (EPH) enzymes, squalene epoxidase (SQE) enzymes, or combinations thereof. This application describes the identification of improved UGT and CDS enzymes for mogrol and mogroside production. Enzymes and host cells described in this application can be used for making mogrol, mogrosides, and precursors thereof.

Synthesis of Mogrol and Mogrosides FIGs. 1A-1B show putative mogrol synthesis pathways. An early step in the pathway involves conversion of squalene to 2,3-oxidoqualene. As shown in FIG. 1A, 2,3-oxidosqualene can be first cyclized to cucurbitadienol followed by epoxidation to form 24,25- epoxycucurbitadienol, or 2,3-oxidosqualene can be epoxidized to 2,3,22,23-dioxidosqualene and then cyclized to 24,25-epoxycucurbitadienol. Next, the 24,25-epoxycucurbitadienol can be converted to mogrol (an aglycone of mogrosides) following epoxide hydrolysis and then oxidation, or oxidation and then epoxide hydrolysis. As shown in FIG. 1B, 2,3-oxidosqualene can be first cyclized to cucurbitadienol, which is then converted to 1 l-hydroxycucurbitadienol by a cytochrome P450 Cl 1 hydroxylase. Then, a cytochrome P450 Cl 1 hydroxylase may convert 1 l-hydroxycucurbitadienol to l l-hydroxy-24,25-epoxycucurbitadienol. 11 -hydroxy-24, 25- epoxycucurbitadienol may be converted to mogrol by epoxide hydrolase. Cl 1 hydroxylases act in conjunction with cytochrome P450 reductases (not shown in FIGs. 1A-1B).

Mogrol can be distinguished from other cucurbitane triterpenoids by oxygenations at C3, Cl 1, C24, and C25. Glycosylation of mogrol, for example at C3 and/or C24, leads to the formation of mogrosides.

Mogrol precursors include but are not limited to squalene, 2-3-oxidosqualene, 2,3,22,23- dioxidosqualene, cucurbitadienol, 24, 25-expoxycucurbitadienol, 1 l-hydroxycucurbitadienol, 11- hydroxy-24,25-epoxycucurbitadienol, l l-hydroxy-cucurbitadienol, l l-oxo-cucurbitadienol, and 24,25-dihydroxycucurbitadienol. The term“dioxidosqualene” may be used to refer to 2,3,22,23- diepoxy squalene or 2,3,22,23-dioxido squalene. The term“2,3 -epoxy squalene” may be used interchangeably with the term“2-3-oxidosqualene.” As used in this application, mogroside precursors include mogrol precursors, mogrol and mogrosides.

Examples of mogrosides include, but are not limited to, mogroside I-Al (MIA1), mogroside IE (MIE), mogroside II-A1 (MIIA1), mogroside II-A2 (MIIA2), mogroside III-A1 (MIIIA1), mogroside II-E (MIIE), mogroside III (Mill), siamenoside I, mogroside IV, mogroside IVa, isomogroside IV, mogroside III-E (MIIIE), mogroside V, and mogroside VI. In some embodiments, the mogroside produced is siamenoside I, which may be referred to as Siam. In some embodiments, the mogroside produced is MIIIE.

In other embodiments, a mogroside is a compound of Formula 1:

In some embodiments, the methods described in this application may be used to produce any of the compounds described in and incorporated by reference from US 2019/0071705, including compounds 1-20 as disclosed in US 2019/0071705. In some embodiments, the methods described in this application may be used to produce variants of any of the compounds described in and incorporated by reference from US 2019/0071705, including variants of compounds 1-20 as disclosed in US 2019/0071705. For example, a variant of a compound described in US 2019/0071705 can comprise a substitution of one or more alpha-glucosyl linkages in a compound described in US 2019/0071705 with one or more beta-glucosyl linkages. In some embodiments, a variant of a compound described in US 2019/0071705 comprises a substitution of one or more beta-glucosyl linkages in a compound described in US 2019/0071705 with one or more alpha-glucosyl linkages. In some embodiments, a variant of a compound described in US 2019/0071705 is a compound of Formula 1 shown above. Cucurbitadienol synthase (CDS) enzymes

Aspects of the present disclosure provide cucurbitadienol synthase (CDS) enzymes, which may be useful, for example, in the production of a cucurbitadienol compound, such as 24- 25 epoxy-cucurbitadienol or cucurbitadienol. CDSs are capable of catalyzing the formation of cucurbitadienol compounds, such as 24-25 epoxy-cucurbitadienol or cucurbitadienol from oxidosqualene ( e.g ., 2-3-oxidosqualene or 2,3; 22,23 -diepoxysqualene).

In some embodiments, CDS enzymes have a leucine residue corresponding to position 123 of SEQ ID NO: 74 that distinguishes them from other oxidosqualene cyclases, as discussed in Takase el al. Org. Biomol. Chem., 2015,13, 7331-7336, which is incorporated by reference in its entirety.

CDSs of the present disclosure may comprise a sequence that is at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical, including all values in between, to a nucleic acid or amino acid sequence in Table 2 or to a sequence selected from SEQ ID NOs: 1-80.

In some embodiments a CDS enzyme corresponds to SEQ ID NO: 43, SEQ ID NO: 52, or SEQ ID NO: 49.

In some embodiments, a polynucleotide sequence encoding a CDS enzyme may be re coded for expression in a particular host cell, including S. cerevisiae. In some embodiments, a re-coded polynucleotide sequence encoding a CDS enzyme corresponds to SEQ ID NO: 34.

In some embodiments, a polynucleotide sequence encoding a CDS is at least 90% identical to SEQ ID NOs: 3, 9, or 12. In some embodiments, a CDS is at least 90% identical to SEQ ID NOs: 43, 49, or 52.

In some embodiments, a CDS of the present disclosure is capable of using oxidosqualene (e.g., 2,3-oxidosqualene or 2,3; 22,23 -diepoxy squalene) as a substrate. In some embodiments, a CDS of the present disclosure is capable of producing cucurbitadienol compounds (e.g., 24-25 epoxy-cucurbitadienol or cucurbitadienol). In some embodiments, a CDS of the present disclosure catalyzes the formation of cucurbitadienol compounds (e.g., 24-25 epoxy- cucurbitadienol or cucurbitadienol) from oxidosqualene (e.g., 2-3-oxidosqualene or 2,3; 22,23- diepoxysqualene) .

It should be appreciated that activity of a CDS can be measured by any means known to one of ordinary skill in the art. In some embodiments, the activity of a CDS may be measured as the normalized peak area of cucurbitadienol produced. In some embodiments, this activity is measured in arbitrary units. In some embodiments, the activity, such as specific activity, of a CDS of the present disclosure is at least 1.1 fold (e.g., at least 1.3 fold, at least 1.5 fold, at least 1.7 fold, at least 1.9 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, or at least 100 fold, including all values in between) greater than that of a control CDS.

It should be appreciated that one of ordinary skill in the art would be able to characterize a protein as a CDS enzyme based on structural and/or functional information associated with the protein. For example, in some embodiments, a protein can be characterized as a CDS enzyme based on its function, such as the ability to produce cucurbitadienol compounds (e.g., 24-25 epoxy-cucurbitadienol or cucurbitadienol) using oxidosqualene (e.g., 2,3-oxidosqualene or 2,3; 22,23 -diepoxysqualene) as a substrate. In some embodiments, a protein can be characterized, at least in part, as a CDS enzyme based on the presence of a leucine residue at a position corresponding to position 123 of SEQ ID NO: 73.

In some embodiments, a CDS comprises the motif GXiWASDLGGP (SEQ ID NO: 331), wherein Xi is N or H. In some embodiments, the motif GXiWASDLGGP (SEQ ID NO: 331) is located in the CDS at residues corresponding to positions 117-126 in SEQ ID NO: 73.

In some embodiments, a CDS comprises the motif DXiGWL (SEQ ID NO: 332), wherein Xi is H or Q. In some embodiments, the motif DXiGWL (SEQ ID NO: 332) is located in the CDS at residues corresponding to positions 479-483 in SEQ ID NO: 73.

In some embodiments, a CDS comprises the motif CWGVCFTYAGW (SEQ ID NO: 333). In some embodiments, the motif CWGVCFTYAGW (SEQ ID NO: 333) is located in the CDS at residues corresponding to positions 612-622 in SEQ ID NO: 73.

In some embodiments, a CDS comprises the motif GHWASDLGGP (SEQ ID NO: 334). In some embodiments, the motif GHWASDLGGP (SEQ ID NO: 334) is located in the CDS at residues corresponding to positions 117-126 in SEQ ID NO: 73. In some embodiments, a CDS comprises the motif DQGWL (SEQ ID NO: 335). In some embodiments, the motif DQGWL (SEQ ID NO: 335) is located in the CDS at residues corresponding to positions 479-483 in SEQ ID NO: 73.

In some embodiments, a CDS comprises the motif GHWASDLGGP (SEQ ID NO: 334), the motif DQGWL (SEQ ID NO: 335), and/or the motif CWGVCFTYAGW (SEQ ID NO: 333).

In some embodiments, a CDS comprises a leucine at a residue corresponding to position 123 in SEQ ID NO: 73. In some embodiments, a CDS comprises a leucine at a residue corresponding to position 483 in SEQ ID NO: 73. In some embodiments, a CDS comprises a cysteine at a residue corresponding to position 612 in SEQ ID NO: 73, a glycine at a residue corresponding to position 614 in SEQ ID NO: 73, an alanine at a residue corresponding to position 620 in SEQ ID NO: 73, and/or a glycine at a residue corresponding to position 621 in SEQ ID NO: 73. In some embodiments, a CDS comprises a leucine at a residue corresponding to position 123 in SEQ ID NO: 73, a leucine at a residue corresponding to position 483 in SEQ ID NO: 73, a cysteine at a residue corresponding to position 612 in SEQ ID NO: 73, a glycine at a residue corresponding to position 614 in SEQ ID NO: 73, an alanine at a residue corresponding to position 620 in SEQ ID NO: 73, and/or a glycine at a residue corresponding to position 621 in SEQ ID NO: 73.

In some embodiments, a CDS comprises the motif GHWANDLGGP (SEQ ID NO: 336). In some embodiments, the motif GHWANDLGGP (SEQ ID NO: 336) is located in the CDS at residues corresponding to positions 117-126 in SEQ ID NO: 73.

In some embodiments, a CDS comprises the motif DXiGWL (SEQ ID NO: 332). In some embodiments, the motif DXiGWL (SEQ ID NO: 332) is located in the CDS at residues corresponding to positions 479-483 in SEQ ID NO: 73.

In some embodiments, a CDS comprises the motif CWGVCYTYAGW (SEQ ID NO: 337). In some embodiments, the motif CWGVCYTYAGW (SEQ ID NO: 337) is located in the CDS at residues corresponding to positions 612-622 in SEQ ID NO: 73.

In some embodiments, a CDS comprises: the motif GHWANDLGGP (SEQ ID NO: 336), located at residues corresponding to positions 117-126 in SEQ ID NO: 73; the motif DQGWL (SEQ ID NO: 335), located at residues corresponding to positions 479-483 in SEQ ID NO: 73; and/or the motif CWGVCYTYAGW (SEQ ID NO: 337), located at residues corresponding to positions 612-622 in SEQ ID NO: 73.

In some embodiments, a host cell that comprises a heterologous polynucleotide encoding a CDS enzyme produces at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more cucurbitadienol compound compared to the same host cell that does not express the heterologous gene.

In some embodiments, a host cell that comprises a heterologous polynucleotide encoding a CDS enzyme produces at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more cucurbitadienol compound relative to a control host cell, wherein the control host cell expresses S. grosvenorii CDS, encoded by a polynucleotide corresponding to SEQ ID NO:33. Throughout this disclosure, host cells that express any of the heterologous

polynucleotides described in this application may be compared to a control host cell. It should be appreciated that a control host cell may have the same genetic background as a host cell that is expressing a specific heterologous polynucleotide sequence, except that the control host cell would not express the same specific heterologous polynucleotide sequence.

In other embodiments, a protein can be characterized as a CDS enzyme based on the percent identity between the protein and a known CDS enzyme. For example, the protein may be at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical, including all values in between, to any of the CDS sequences described in this application or the sequence of any other CDS enzyme. In other embodiments, a protein can be characterized as a CDS enzyme based on the presence of one or more domains in the protein that are associated with CDS enzymes. For example, in certain embodiments, a protein is characterized as a CDS enzyme based on the presence of a substrate channel and/or an active-site cavity characteristic of CDS enzymes known in the art. In some embodiments, the active site cavity comprises a residue that acts a gate to this channel, helping to exclude water from the cavity. In some embodiments, the active-site comprises a residue that acts a proton donor to open the epoxide of the substrate and catalyze the cyclization process.

In other embodiments, a protein can be characterized as a CDS enzyme based on a comparison of the three-dimensional structure of the protein compared to the three-dimensional structure of a known CDS enzyme. It should be appreciated that a CDS enzyme can be a synthetic protein.

UDP-glycosyltransf erases (UGT) enzymes

Aspects of the present disclosure provide UDP-glycosyltransferase enzymes (UGTs), which may be useful, for example, in the production of a mogroside (e.g., mogroside I-Al (MIA1), mogroside I-E (MIE), mogroside II-A1 (MIIA1), mogroside II-A2 (MIIA2), mogroside III-A1 (MIIIA1), mogroside II-E (MIIE), mogroside III (Mill), siamenoside I, mogroside III-E (MIIIE), mogroside IV, mogroside IVa, isomogroside IV, mogroside V, or mogroside VI).

As used in this application, a“UGT” refers to an enzyme that is capable of catalyzing the addition of the glycosyl group from a UTP-sugar to a compound (e.g., mogroside or mogrol). A UGT may be a primary and/or a secondary UGT. A“primary” UGT refers to a UGT that is capable of catalyzing the addition of a glycosyl group to a position on a compound that does not comprise a glycosyl group. For example, a primary UGT may be capable of adding a glycosyl group to the C3 and/or C24 position of an isoprenoid substrate ( e.g . , mogrol). See, e.g., FIG. 1C. A“secondary” UGT refers to a UGT that is capable of catalyzing the addition of a glycosyl group to a position on a compound that already comprises a glycosyl group. See, e.g., FIG. 1D. As a non-limiting example, a secondary UGT may add a glycosyl group to a mogroside I-Al (MIA1), mogroside I-E (MIE), mogroside II-A1 (MIIA1), mogroside II-A2 (MIIA2), mogroside III-A1 (MIIIA1), mogroside II-E (MIIE), mogroside III (Mill), siamenoside I, mogroside III-E (MIIIE), mogroside IV, mogroside IVa, isomogroside IV, mogroside V, and/or mogroside VI.

Structurally, UGTs often comprise a UDPGT (Prosite: PS00375) domain and a catalytic dyad. As a non-limiting example, one of ordinary skill in the art may identify a catalytic dyad in a UGT by aligning the UGT sequence to UGT94-289-1 (a wildtype UGT sequence from the monk fruit Siraitia grosvenorii ) and identifying the two residues in the UGT that correspond to histidine 21 (H21) and aspartate 122 (D122) of UGT94-289- 1.

The amino acid sequence for UGT94-289- 1 is:

MD AQRGHTTTILMFPWLG Y GHLS AFLELAKS LS RRNFHIYFCS T S VNLD AIKPKL PSSSSSDSIQFVEFCFPSSPDQFPPHFHTTNAFPPHFMPTFHQAFSMAAQHFAAIFHTFA P HFFIYDS F QPW APQFAS S FNIP AINFNTT GAS VFTRMFH ATH YPS S KFPIS EFVFHD YWK AMY S A AGG A VTKKDHKIGETFANCFH AS C S VIFIN S FREFEEK YMD YES VFFNKKV VP V GPLV YEPN QDGEDEG Y S S IKNWLDKKEPS S T VFV S FGS E YFPS KEEMEEIAHGLE AS E VH FIWVVRFPQGDNTSAIEDALPKGFLERVGERGMVVKGWAPQAKILKHWSTGGFVSHCG WNS VMES MMF G VPIIG VPMHLDQPFN AGL AEE AG V G VE AKRDPDGKIQRDE V AKLIKE V V VEKTRED VRKK AREMS EILRS KGEEKMDEM V A AIS LFLKI (SEQ ID NO: 109).

A non-limiting example of a nucleic acid sequence encoding UGT94-289- 1 is:

atggacgcgcaacgcggacatacgactaccatcctgatgtttccgtggttggggtacggc caccttagtgcattcctcgaattagc caagagcttgtcgcgtaggaactttcatatttatttctgttccacatctgtcaatttaga tgctataaaacccaaactaccatcatcttcaagttccg attctattcagcttgtagagttatgcttgccttcctcgccagaccaactacccccacacc tgcatacaactaatgctctacctccacatctaatgc ctaccctgcaccaggccttttcaatggcagctcaacattttgcagctatattacatactt tagcaccgcacttgttaatctatgattcgttccagcct tgggcgccacaattggccagctctcttaacattcctgctattaattttaataccacgggt gccagtgtgctaacaagaatgttacacgcgactca ttacccatcttcaaagttcccaatctccgaatttgttttacatgattattggaaagcaat gtattcagcagctggtggtgctgttacaaaaaaggac cataaaataggagaaaccttggcaaactgtttacacgcttcttgctcggtaattctgatc aattcattcagagagttggaagaaaaatacatgga ttacttgtctgtcttactaaacaagaaagttgtgcccgtgggtccgcttgtttatgagcc aaaccaagatggcgaagacgaaggttatagttcg ataaagaattggctcgataaaaaggagccctcctcaactgtctttgtttccttcgggtcc gaatattttccgtccaaagaagaaatggaagaaat tgcccatggcttggaggctagcgaggtacactttatttgggtcgttagattcccacaagg agacaatacttctgcaattgaagatgcccttccta agggttttcttgagcgagtgggcgaacgtggaatggtggttaagggttgggctcctcagg ccaaaattttgaaacattggagcacaggcggt ttcgtaagtcattgtggatggaatagtgttatggagagcatgatgtttggtgtacccata ataggtgttccgatgcatttagatcaaccatttaatg cagggctcgcggaagaagcaggagtaggggtagaggctaaaagggaccctgatggtaaga tacagagagatgaagtcgctaaactgat caaagaagtggttgtcgaaaaaacgcgcgaagatgtcagaaagaaggctagggaaatgtc tgaaattttacgttcgaaaggtgaggaaaa gatggacgagatggttgcagccattagtctcttcttgaagatataa (SEQ ID NO: 93).

One of ordinary skill in the art would readily recognize how to determine for any UGT enzyme what amino acid residue corresponds to a specific amino acid residue in UGT94-289-1 (SEQ ID NO: 109) by, for example, aligning sequences and/or by comparing secondary or tertiary structures.

In certain embodiments, a UGT of the present disclosure comprises one or more structural motifs corresponding to a structural motif in wild-type UGT94-289-1 ( e.g ., corresponding to a structural motif that is shown in Table 5). In some embodiments, a UGT comprises structural motifs corresponding to all structural motifs in Table 5. In some

embodiments, a UGT comprises a structural motif that corresponds to some but not all structural motifs shown in Table 5. In some embodiments, some structural motifs may diverge by having different lengths or different helicity. For example, a UGT of the present disclosure may comprise extended versions of loops 11, 16, 20, or a combination thereof in UGT94-289-1. A UGT of the present disclosure may comprise loops that have greater helicity than their counterpart in UGT94-289-1 (e.g., loops 11, 16, 20, or a combination thereof in UGT94-289-1).

In some embodiments, a UGT is a circularly permutated version of a reference UGT. In some embodiments, a UGT comprises a sequence that includes at least two motifs from Table 5 in a different order than a reference UGT. For example, if UGT94-289-1 is used as a reference UGT and comprises a first motif that is located C-terminal to a second motif, the first motif may be located N-terminal to the second motif in a circularly permutated UGT.

A UGT may comprise one or more motifs corresponding to one or more motifs selected from Loop 1, Beta Sheet 1, Loop 2, Alpha Helix 1, Loop 3, Beta Sheet 2, Loop 4, Alpha Helix 2, Loop 5, Beta Sheet 3, Loop 6, Alpha Helix 3, Loop 7, Beta Sheet 4, Loop 8, Alpha Helix 4, Loop 9, Beta Sheet 5, Loop 10, Alpha Helix 5, Loop 11, Alpha Helix 6, Loop 12, Alpha Helix 7, Loop 13, Beta Sheet 6, Loop 14, Alpha Helix 8, and Loop 15 from Table 5 located C-terminal to one or more motifs corresponding to one or more motifs selected from Beta Sheet 7, Loop 16, Alpha Helix 9, Loop 17, Beta Sheet 8, Loop 18, Alpha Helix 10, Loop 19, Beta Sheet 9, Alpha Helix 11, Loop 20, Alpha Helix 12, Loop 21, Beta Sheet 10, Loop 22, Alpha Helix 13, Loop 23, Beta Sheet 11, Loop 24, Alpha Helix 14, Loop 25, Beta Sheet 12, Loop 26, Alpha Helix 15, Loop 27, Beta Sheet 13, Loop 28, Alpha Helix 16, Loop 29, Alpha Helix 17, Loop 30, Alpha Helix 18, and Loop 31 in Table 5.

In some embodiments, the N-terminal portion of a UGT comprises a catalytic site, including a catalytic dyad, and/or a substrate-binding site. In some embodiments, the C-terminal portion of a UGT comprises a cofactor-binding site. For example, the N-terminal portion of UGT94-289-1 comprises a catalytic dyad corresponding to residues 21 and 122 of wildtype UGT94-289-1 ( e.g ., histidine 21 and aspartate acid 122). The C-terminal portion of UGT94- 289-1 comprises a cofactor-binding site.

Aspects of the disclosure include UGTs that have been circularly permutated. In some embodiments, in a circularly permutated version of a UGT, the N-terminal portion and the C- terminal portions may be reversed in whole or in part. For example, the C-terminal portion of a circularly permutated UGT may comprise a catalytic site, including a catalytic dyad, and/or a substrate-binding site, while the N-terminal portion may comprise a cofactor-binding site.

In some embodiments, a circularly permutated version of a UGT comprises a

heterologous polynucleotide encoding a UGT, wherein the UGT comprises: a catalytic dyad and a cofactor binding site, wherein the catalytic dyad is located C-terminal to the cofactor-binding site.

A circularly permutated UGT encompassed by the disclosure may exhibit different properties from the same UGT that has not undergone circular permutation. In some

embodiments, a host cell expressing such a circularly permutated version of a UGT produces in the presence of at least one mogroside precursor at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more of one or more mogrosides relative to a host cell that comprises a heterologous polynucleotide encoding a reference UGT that is not circularly permutated, such as wild-type UGT94-289-1 (SEQ ID NO: 109). In some embodiments, a host cell expressing such a circularly permutated version of a UGT produces in the presence of at least one mogroside precursor at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% less of one or more mogrosides relative to a host cell that comprises a heterologous polynucleotide encoding a reference UGT that is not circularly permutated, such as wild-type UGT94-289-1 (SEQ ID NO: 109).

In some embodiments, in a circularly permutated version of a UGT, the N-terminal portion of a UGT comprises residues that are usually present in the C-terminal portion of a UGT, such as UGT94-289-1. In some embodiments, in a circularly permutated version of a UGT, the C-terminal portion of a UGT comprises residues that are usually present in the N-terminal portion of a UGT, such as UGT94-289-1.

In some embodiments, the N-terminal portion of a UGT, such as UGT94-289-1, corresponds to approximately residues 2-122, residues 2-123, residues 2-124, residues 2-125, residues 2-126, residues 2-127, residues 2-128, residues 2-129, residues 2-130, residues 2-131, residues 2-132, residues 2-133, residues 2-134, residues 2-135, residues 2-136, residues 2-137, residues 2-138, residues 2-139, residues 2-140, residues 2-141, residues 2-142, residues 2-143, residues 2-144, residues 2-145, residues 2-146, residues 2-147, residues 2-148, residues 2-149, residues 2-150, residues 2-151, residues 2-152, residues 2-153, residues 2-154, residues 2-155, residues 2-156, residues 2-157, residues 2-158, residues 2-159, residues 2-160, residues 2-161, residues 2-162, residues 2-163, residues 2-164, residues 2-165, residues 2-166, residues 2-167, residues 2-168, residues 2-169, residues 2-170, residues 2-171, residues 2-172, residues 2-173, residues 2-174, residues 2-175, residues 2-176, residues 2-177, residues 2-178, residues 2-179, residues 2-180, residues 2-181, residues 2-182, residues 2-183, residues 2-184, residues 2-185, residues 2-186, residues 2-187, residues 2-188, residues 2-189, residues 2-190, residues 2-191, residues 2-192, residues 2-193, residues 2-194, residues 2-195, residues 2-196, residues 2-197, residues 2-198, residues 2-199, residues 2-200, residues 2-201, residues 2-202, residues 2-203, residues 2-204, residues 2-205, residues 2-206, residues 2-207, residues 2-208, residues 2-209, residues 2-210, residues 2-211, residues 2-212, residues 2-213, residues 2-214, residues 2-215, residues 2-216, residues 2-217, residues 2-218, residues 2-219, residues 2-220, residues 2-221, residues 2-222, residues 2-223, residues 2-224, residues 2-225, residues 2-226, residues 2-227, residues 2-228, residues 2-229, residues 2-230, residues 2-231, residues 2-232, residues 2-233, residues 2-234, residues 2-235, residues 2-236, residues 2-237, residues 2-238, residues 2-239, residues 2-240, residues 2-241, residues 2-242, residues 2-243, residues 2-244, residues 2-245, residues 2-246, residues 2-247, residues 2-248, residues 2-249, residues 2-250, residues 2-251, or residues 2-252 of a UGT, such as UGT94-289-1 (SEQ ID NO: 109), or corresponding residues in another UGT.

In some embodiments, the C-terminal domain of a UGT, such as UGT94-289-1, corresponds to approximately residues 123-456, residues 124-456, residues 125-456, residues 126-456, residues 127-456, residues 128-456, residues 129-456, residues 130-456, residues 131- 456, residues 132-456, residues 133-456, residues 134-456, residues 135-456, residues 136-456, residues 137-456, residues 138-456, residues 139 -456, residues 140-456, residues 141-456, residues 142-456, residues 143-456, residues 144 -456, residues 145-456, residues 146-456, residues 147-456, residues 148-456, residues 149 -456, residues 150-456, residues 151-456, residues 152-456, residues 153-456, residues 154 -456, residues 155-456, residues 156-456, residues 157-456, residues 158-456, residues 159 -456, residues 160-456, residues 161-456, residues 162-456, residues 163-456, residues 164 -456, residues 165-456, residues 166-456, residues 167-456, residues 168-456, residues 169 -456, residues 170-456, residues 171-456, residues 172-456, residues 173-456, residues 174 -456, residues 175-456, residues 176-456, residues 177-456, residues 178-456, residues 179 -456, residues 180-456, residues 181-456, residues 182-456, residues 183-456, residues 184 -456, residues 185-456, residues 186-456, residues 187-456, residues 188-456, residues 189 -456, residues 190-456, residues 191-456, residues 192-456, residues 193-456, residues 194 -456, residues 195-456, residues 196-456, residues 197-456, residues 198-456, residues 199 -456, residues 200-456, residues 201-456, residues 202-456, residues 203-456, residues 204 -456, residues 205-456, residues 206-456, residues 207-456, residues 208-456, residues 209 -456, residues 210-456, residues 211-456, residues 212-456, residues 213-456, residues 214 -456, residues 215-456, residues 216-456, residues 217-456, residues 218-456, residues 219 -456, residues 220-456, residues 221-456, residues 222-456, residues 223-456, residues 224 -456, residues 225-456, residues 226-456, residues 227-456, residues 228-456, residues 229 -456, residues 230-456, residues 231-456, residues 232-456, residues 233-456, residues 234 -456, residues 235-456, residues 236-456, residues 237-456, residues 238-456, residues 239 -456, residues 240-456, residues 241-456, residues 242-456, residues 243-456, residues 244 -456, residues 245-456, residues 246-456, residues 247-456, residues 248-456, residues 249 -456, residues 250-456, or residues 251-456 of a UGT, such as UGT94-289-1 (SEQ ID NO: 109; ), or corresponding residues in another UGT. In some embodiments, a UGT of the present disclosure comprises a sequence ( e.g ., nucleic acid or amino acid sequence) that is at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical, including all values in between, to a sequence in Tables 3, 6 or 7, to a sequence selected from SEQ ID NOs: 207-242, SEQ ID NOs: 243-316, SEQ ID NOs: 225-242, SEQ ID NOs: 280-316, SEQ ID NOs: 317-322, SEQ ID NOs: 323-328, or SEQ ID NO: 330 or to any of the UGTs disclosed in this application.

In some embodiments, a UGT of the present disclosure may comprise an amino acid substitution at an amino acid residue corresponding to an amino acid residue in wild-type UGT94-289-1 (SEQ ID NO: 109). For example, an amino acid residue that contains a substitution can be an amino acid that corresponds to an amino acid residue in wild-type UGT94- 289-1 (SEQ ID NO: 109) selected from, e.g., S123; F124; N143; T144; T145; V149; Y179; G18; S180; A181; G184; A185; V186; T187; K189; Y19; H191; K192; G194; E195; A198; F276; N355; H373; L374; N47; H83; T84; T85; N86; P89; and/or L92. Non-limiting examples of such amino acid substitutions include: S123 may be mutated to alanine, cysteine, glycine or valine, or to any conservative substitution of alanine, cysteine, glycine or valine; F124 may be mutated to tyrosine or to any conservative substitution of tyrosine; N143 may be mutated to alanine, cysteine, glutamate, isoleucine, leucine, methionine, glutamine, serine, threonine or valine, or to any conservative substitution of alanine, cysteine, glutamate, isoleucine, leucine, methionine, glutamine, serine, threonine or valine; T144 may be mutated to alanine, cysteine, asparagine or proline, or to any conservative substitution of alanine, cysteine, asparagine or proline; T145 may be mutated to alanine, cysteine, glycine, methionine, asparagine, glutamine, or serine, or any conservative substitution of alanine, cysteine, glycine, methionine, asparagine, glutamine, or serine; V149 may be mutated to cysteine, leucine or methionine, or to any conservative substitution of cysteine, leucine or methionine; Y 179 may be mutated to glutamate,

phenylalanine, histidine, isoleucine, lysine, leucine, valine, or tryptophan, or to any conservative substitution glutamate, phenylalanine, histidine, isoleucine, lysine, leucine, valine, or tryptophan; G18 may be mutated to serine or to any conservative substitution of serine; S180 may be mutated to alanine or valine, or to any conservative substitution of alanine or valine; A181 may be mutated to lysine or threonine, or to any conservative substitution of lysine or threonine; G184 may be mutated to alanine, cysteine, aspartate, glutamate, phenylalanine, histidine, isoleucine, lysine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, or tyrosine, or to any conservative substitution of alanine, cysteine, aspartate, glutamate, phenylalanine, histidine, isoleucine, lysine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, or tyrosine; A 185 may be mutated to cysteine, aspartate, glutamate, glycine, lysine, leucine, methionine, asparagine, proline, glutamine, threonine, tryptophan or tyrosine, or to any conservative substitution of cysteine, aspartate, glutamate, glycine, lysine, leucine, methionine, asparagine, proline, glutamine, threonine, tryptophan or tyrosine; VI 86 may be mutated to alanine, cysteine, aspartate, glutamate, glycine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, threonine, tryptophan, or tyrosine, or to any

conservative substitution of alanine, cysteine, aspartate, glutamate, glycine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, threonine, tryptophan, or tyrosine; T187 may be mutated to alanine, cysteine, aspartate, glutamate, glycine, histidine, isoleucine, lysine, leucine, asparagine, proline, arginine, serine, valine, tryptophan, or tyrosine, or to any conservative substitution of alanine, cysteine, aspartate, glutamate, glycine, histidine, isoleucine, lysine, leucine, asparagine, proline, arginine, serine, valine, tryptophan, or tyrosine; K189 may be mutated to alanine, cysteine, aspartate, glutamate, phenylalanine, glycine, histidine, isoleucine, leucine, methionine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine, or to any conservative substitution thereof of alanine, cysteine, aspartate, glutamate, phenylalanine, glycine, histidine, isoleucine, leucine, methionine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine; Y19 may be mutated to

phenylalanine, histidine, leucine, or valine, or to any conservative substitution of phenylalanine, histidine, leucine, or valine; H191 may be mutated to alanine, cysteine, aspartate, glutamate, glycine, lysine, methionine, proline, glutamine, serine, threonine, valine, tryptophan, or tyrosine, or to any conservative substitution of mutated to alanine, cysteine, aspartate, glutamate, glycine, lysine, methionine, proline, glutamine, serine, threonine, valine, tryptophan, or tyrosine; K192 may be mutated to cysteine or phenylalanine, or to any conservative substitution of cysteine or phenylalanine; G194 may be mutated to aspartate, leucine, methionine, asparagine, proline, serine, or tryptophan, or to any conservative substitution of aspartate, leucine, methionine, asparagine, proline, serine, or tryptophan; El 95 may be mutated to alanine, isoleucine, lysine, leucine, asparagine, glutamine, serine, threonine, or tyrosine, or to any conservative substitution of alanine, isoleucine, lysine, leucine, asparagine, glutamine, serine, threonine, or tyrosine; A 198 may be mutated to cysteine, aspartate, glutamate, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, or tyrosine, or to any conservative substitution of cysteine, aspartate, glutamate, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, or tyrosine; F276 may be mutated to cysteine or glutamine, or to any conservative substitution of cysteine or glutamine; N355 may be mutated to glutamine or serine, or any conservative substitution thereof; H373 may be mutated to lysine, leucine, methionine, arginine, valine, or tyrosine, or to any conservative substitution of lysine, leucine, methionine, arginine, valine, or tyrosine; L374 may be mutated to alanine, cysteine, phenylalanine, histidine, methionine, asparagine, glutamine, serine, threonine, valine, tryptophan, or tyrosine, or to any conservative substitution of alanine, cysteine, phenylalanine, histidine, methionine, asparagine, glutamine, serine, threonine, valine, tryptophan, or tyrosine; N47 may be mutated to glycine or to any conservative substitution of glycine; H83 may be mutated to glutamine or tryptophan, or to any conservative substitution of glutamine or tryptophan; T84 may be mutated to tyrosine or to any conservative substitution of tyrosine; T85 may be mutated to glycine, lysine, proline, serine, or tyrosine, or to any conservative substitution of glycine, lysine, proline, serine, or tyrosine;

N86 may be mutated to alanine, cysteine, glutamate, isoleucine, lysine, leucine, serine, tryptophan, or tyrosine, or to any conservative substitution of alanine, cysteine, glutamate, isoleucine, lysine, leucine, serine, tryptophan, or tyrosine; P89 may be mutated to methionine or serine or to any conservative substitution of methionine or serine; and/or L92 may be mutated to histidine or lysine or to any conservative substitution of histidine or lysine.

One of ordinary skill in the art would readily recognize how to determine for any UGT enzyme what amino acid residue corresponds to a specific amino acid residue in UGT94-289-1 (SEQ ID NO: 109) by, for example, aligning sequences and/or by comparing secondary structures. As a non-limiting example, a sequence alignment ( e.g ., conducted using Clustal Omega, see e.g., Larkin et ah, Bioinformatics . 2007 Nov l;23(2l):2947-8) is provided in FIG. 9 between UGT94-289-1 (SEQ ID NO: 109) and U73C6 (SEQ ID NO: 103). For example, in FIG. 9, the residue in U73C6 (SEQ ID NO: 103) corresponding to position 123 in UGT94-289-1 (SEQ ID NO: 109) is methionine (M). As another non-limiting example, the residue in U73C6 (SEQ ID NO: 103) corresponding to position 143 in UGT94-289-1 (SEQ ID NO: 109) is histidine (H) (FIG. 9). As another non-limiting example, the residue in U73C6 (SEQ ID NO: 103) corresponding to position 273 in UGT94-289-1 (SEQ ID NO: 109) is phenylalanine (F) (FIG. 9).

In some embodiments, a UGT comprises an amino acid substitution corresponding to the amino acid substitutions in UGT94-289-1 set forth in Table 4.

A UGT of the present disclosure can comprise a conservative amino acid substitution and/or a non-conservative amino acid substitution. In some embodiments, a UGT of the present disclosure comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 conservative amino acid substitution(s). In some embodiments, a UGT of the present disclosure comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 non-conservative amino acid substitutions. In some embodiments, a conservative or non-conservative amino acid substitution is not located in a conserved region of a UGT protein. In some embodiments, a conservative or non-conservative amino acid substitution is not located in a region corresponding to: residues 83 to 92; residues 179 to 198; residue N143; residue L374; residue H21; or residue D122 of wild-type UGT94-289-1. One of ordinary skill in the art would readily be able to test a UGT that comprises a conservative and/or non-conservative substitution to determine whether the conservative and/or non-conservative substitution impacts the activity or function of the UGT.

In some embodiments, a UGT enzyme contains an amino acid substitution located within 10 angstrom, 9 angstrom 8 angstrom, 7 angstrom, 6 angstrom, 5 angstrom, 4 angstrom, 3 angstrom, 2 angstrom, or within 1 angstrom (including all values in between) of a catalytic dyad. The catalytic dyad may correspond to residues 21 and 122 of wildtype UGT94-289-1 ( e.g ., histidine 21 and aspartate acid 122). It should be appreciated that one of ordinary skill in the art would readily recognize how to determine to corresponding location of the catalytic dyad in any UGT enzyme, for example, by aligning the sequence and/or by comparing the secondary structure with UGT94-289-1 (SEQ ID NO: 109).

In some embodiments, a UGT enzyme contains an amino acid substitution at an amino acid residue located in one or more structural motifs of the UGT. Non-limiting examples of secondary structures in UGTs, such as UGT94-289-1 (SEQ ID NO: 109), include: the loop between beta sheet 4 and alpha helix 5; beta sheet 5; the loop between beta sheet 5 and alpha helix 6; alpha helix 6; the loop between alpha helix 6 & 7; the loop between beta sheet 1 & alpha helix 1; alpha helix 7; the loop between alpha helix 7 & 8; alpha helix 1; alpha helix 8; the loop between beta sheet 8 & alpha helix 13; alpha helix 17; the loop between beta sheet 12 & alpha helix 18; alpha helix 2; loop between beta sheet 3 & alpha helix 3; alpha helix 3; and the loop between alpha helix 3 & 4; loop 8; beta sheet 5; loop 10; alpha helix 5; loop 11; loop 2; alpha helix 6; loop 12; alpha helix 1; alpha helix 7; loop 18; alpha helix 14; loop 26; alpha helix 2; loop 6; and alpha helix 3.

In some embodiments: the amino acid residue located in loop 8 is a residue

corresponding to S123 or F124 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in beta sheet 5 is a residue corresponding to N143 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in loop 10 is a residue corresponding to T 144 or T 145 in UGT94- 289-1 (SEQ ID NO: 109); the amino acid residue located in alpha helix 5 is a residue

corresponding to V149 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in loop 11 is a residue corresponding to Y179 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in loop 2 is a residue corresponding to G18 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in alpha helix 6 is a residue corresponding to S 180 or Al 81 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in loop 12 is a residue corresponding to G184, A185, V186, T187, or K189 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in alpha helix 1 is a residue corresponding to Y 19 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in alpha helix 7 is a residue corresponding to H191, K192, G194, E195, or A198 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in loop 18 is a residue corresponding to F276 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in alpha helix 14 is a residue corresponding to N355 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in loop 26 is a residue corresponding to H373 or L374 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in alpha helix 2 is a residue corresponding to N47 in UGT94-289-1 (SEQ ID NO: 109); the amino acid residue located in loop 6 is a residue corresponding to H83, T84, T85, or N86 in UGT94-289-1 (SEQ ID NO: 109); and/or the amino acid residue located in alpha helix 3 is a residue corresponding to P89 or L92 in UGT94-289-1 (SEQ ID NO: 109). In some embodiments, a UGT comprises an amino acid substitution ( e.g ., at least 1, 2, 3, 4, 5, 6, 7, or 8 substitutions) in a region corresponding to residues 83 to 92, 179 to 189, 1 to 82, 93 to 142, 144 to 178, 199 to 373, or 375 to 453 of UGT94-289-1 (SEQ ID NO: 109). In some embodiments, the UGT comprises an amino acid substitution at an amino acid residue corresponding to the amino acid residue in wild-type UGT94-289-1 (SEQ ID NO: 109) selected from: N143 and L374. In some embodiments, the residue corresponding to N143 is mutated to a negatively charged R group, a polar uncharged R group, or a nonpolar aliphatic R group. In some embodiments, the residue corresponding to L374 is mutated to a nonpolar aliphatic R group, a positively charged R group, a polar uncharged R group, or a nonpolar aromatic R group. In some embodiments, a UGT comprises a region that is at least 90% identical to residues 83 to 92 of UGT94-289-1 or at least 95% identical to residues 179 to 198 of UGT94-289-1. A UGT can comprise a region that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical, or is 100% identical, to residues 83 to 92 of UGT94- 289-1. A UGT can comprise a region that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical, or is 100% identical, to residues 179 to 198 of UGT94-289-1 (SEQ ID NO: 109).

In some embodiments, a host cell comprises a heterologous polynucleotide encoding a UGT, wherein the UGT comprises a region that: corresponds to residues 83 to 92 of wild-type UGT94-289-1 (SEQ ID NO: 109), wherein the region comprises an amino acid substitution relative to residues 83 to 92 of wild-type UGT94-289-1 (SEQ ID NO: 109); and/or corresponds to residues 179 to 198 of wild-type UGT94-289-1 (SEQ ID NO: 109), wherein the region comprises an amino acid substitution relative to residues 179 to 198 of wild-type UGT94-289-1 (SEQ ID NO: 109). It should be appreciated that the language“an amino acid substitution” is not limited to one amino acid substitution, but also encompasses embodiments including more than one amino acid substitution. In some embodiments, a host cell comprises a heterologous polynucleotide encoding a UGT, wherein the UGT comprises a region that: corresponds to residues 83 to 92 of wild-type UGT94-289-1 (SEQ ID NO: 109), wherein the region comprises no more than one amino acid substitution relative to residues 83 to 92 of wild-type UGT94-289- 1 (SEQ ID NO: 109); and/or corresponds to residues 179 to 198 of wild-type UGT94-289-1 (SEQ ID NO: 109), wherein the region comprises no more than one amino acid substitution relative to residues 179 to 198 of wild-type UGT94-289-1 (SEQ ID NO: 109).

In some embodiments, the UGT comprises an amino acid substitution at an amino acid residue corresponding to the amino acid residue in wild-type UGT94-289-1 (SEQ ID NO: 109) selected from: H83, T84, T85, N86, P89, L92, Y179, S180, A181, G184, A185, V186, T187, K189, H191, K192, G194, E195, or A198.

In some embodiments, the residue corresponding to H83 is mutated to an amino acid comprising a polar uncharged R group or a nonpolar aromatic R group; the residue

corresponding to T84 is mutated to an amino acid comprising a nonpolar aromatic R group; the residue corresponding to T85 is mutated to an amino acid comprising a nonpolar aliphatic R group, a positively charged R group, a polar uncharged R group, or a nonpolar aromatic R group; the residue corresponding to N86 is mutated to an amino acid comprising a nonpolar aliphatic R group, a polar uncharged R group, a negatively charged R group, a positively charged R group, or a nonpolar aromatic R group; the residue corresponding to P89 is mutated to an amino acid comprising a nonpolar aliphatic R group, or a polar uncharged R group; the residue

corresponding to L92 is mutated to an amino acid comprising a positively charged R group; the residue corresponding to Y 179 is mutated to an amino acid comprising a negatively charged R group, a nonpolar aromatic R group, a positively charged R group, or a nonpolar aliphatic R group; the residue corresponding to S 180 is mutated to an amino acid comprising a nonpolar aliphatic R group; the residue corresponding to A181 is mutated to an amino acid comprising a positively charged R group or a polar uncharged R group; the residue corresponding to G184 is mutated to an amino acid comprising a nonpolar aliphatic R group, a polar uncharged R group, a negatively charged R group, a nonpolar aromatic R group, or a positively charged R group; the residue corresponding to A 185 is mutated to an amino acid comprising a polar uncharged R group, a negatively charged R group, a nonpolar aliphatic R group, a positively charged R group, or a nonpolar aromatic R group; the residue corresponding to VI 86 is mutated to an amino acid comprising a nonpolar aliphatic R group, a polar uncharged R group, a negatively charged R group, a positively charged R group, or a nonpolar aromatic R group; the residue corresponding to T 187 is mutated to an amino acid comprising a nonpolar aliphatic R group, a polar uncharged R group, a negatively charged R group, a positively charged R group, or a nonpolar aromatic R group; the residue corresponding to K189 is mutated to an amino acid comprising a nonpolar aliphatic R group, a polar uncharged R group, a negatively charged R group, a nonpolar aromatic R group, or a positively charged R group; the residue corresponding to H191 is mutated to an amino acid comprising a nonpolar aliphatic R group, a polar uncharged R group, a negatively charged R group, a positively charged R group, or a nonpolar aromatic R group; the residue corresponding to K 192 is mutated to an amino acid comprising a polar uncharged R group or a nonpolar aromatic R group; the residue corresponding to G 194 is mutated to an amino acid comprising a negatively charged R group, a nonpolar aliphatic R group, a polar uncharged R group, or a nonpolar aromatic R group; the residue corresponding to E195 is mutated to an amino acid comprising a nonpolar aliphatic R group, a positively charged R group, a polar uncharged R group, or a nonpolar aromatic R group; and/or the residue corresponding to A198 is mutated to an amino acid comprising a polar uncharged R group, a negatively charged R group, a nonpolar aromatic R group, a positively charged R group, or a nonpolar aliphatic R group.

In some embodiments, the UGT comprises an amino acid substitution at an amino acid residue corresponding to the amino acid residue in wild-type UGT94-289-1 (SEQ ID NO: 109) selected from: N143 and L374. In some embodiments, the residue corresponding to N143 is mutated to a negatively charged R group, a polar uncharged R group, or a nonpolar aliphatic R group. In some embodiments, the residue corresponding to L374 is mutated to a nonpolar aliphatic R group, a positively charged R group, a polar uncharged R group, or a nonpolar aromatic R group.

The UGTs of the present disclosure may be capable of glycosylating mogrol or a mogroside at any of the oxygenated sites (e.g., at C3, Cl 1, C24, and C25). In some

embodiments, the UGT is capable of branching glycosylation (e.g., branching glycosylation of a mogroside at C3 or C24).

Non-limiting examples of suitable substrates for the UGTs of the present disclosure include mogrol and mogrosides (e.g., mogroside IA1 (MIA1), mogroside IE (MIE), mogroside II- A 1 (MIIA1), mogroside III-A1 (MIIIA1), mogroside II-E (MIIE), mogroside III (Mill), or mogroside III-E (MIIIE), siamenoside I).

In some embodiments, the UGTs of the present disclosure are capable of producing mogroside IA1 (MIA1), mogroside IE (MIE), mogroside II-A1 (MIIA1), mogroside II-A2 (MIIA2), mogroside III-A1 (MIIIA1), mogroside II-E (MIIE), mogroside III (Mill), siamenoside I, mogroside III-E (MIIIE), mogroside IV, mogroside IVa, isomogroside IV, and/or mogroside V.

In some embodiments, the UGT is capable of catalyzing the conversion of mogrol to MIA1; mogrol to MIE1; MIA1 to MIIA1; MIE1 to MIIE; MIIA1 to MIIIA1; MIA1 to MIIE; MIIA1 to Mill; MIIIA1 to siamenoside I; MIIE to Mill; Mill to siamenoside I; MIIE to MIIE; and/or MIIIE to siamenoside I.

It should be appreciated that activity, such as specific activity, of a UGT can be measured by any means known to one of ordinary skill in the art. In some embodiments, the activity, such as specific activity, of a UGT ( e.g ., a variant UGT) may be determined by measuring the amount of glycosylated mogroside produced per unit enzyme per unit time. For example, the activity, such as specific activity, may be measured in mmol glycosylated mogroside target produced per gram of enzyme per hour. A non-limiting example of a method to measure activity (e.g., specific activity) is provided in the Examples below. In some embodiments, a UGT of the present disclosure (e.g., variant UGT) may have an activity, such as specific activity, of at least 0.1 mmol (e.g., at least 1 mmol, at least 1.5 mmol, at least 2 mmol, at least 2.5 mmol, at least 3, at least 3.5 mmol, at least 4 mmol, at least 4.5 mmol, at least 5 mmol, at least 10 mmol, including all values in between) glycosylated mogroside target produced per gram of enzyme per hour.

In some embodiments, the activity, such as specific activity, of a UGT of the present disclosure is at least 1.1 fold (e.g., at least 1.3 fold, at least 1.5 fold, at least 1.7 fold, at least 1.9 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, or at least 100 fold, including all values in between) greater than that of a control UGT. In some embodiments, the control UGT is UGT94-289-1 (SEQ ID NO: 109). In some embodiments, for a UGT that has an amino acid substitution, a control UGT is the same UGT but without the amino acid substitution.

It should be appreciated that one of ordinary skill in the art would be able to characterize a protein as a UGT enzyme based on structural and/or functional information associated with the protein. For example, a protein can be characterized as a UGT enzyme based on its function, such as the ability to produce one or more mogrosides in the presence of a mogroside precursor, such as mogrol.

In other embodiments, a protein can be characterized as a UGT enzyme based on the percent identity between the protein and a known UGT enzyme. For example, the protein may be at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical, including all values in between, to any of the UGT sequences described in this application or the sequence of any other UGT enzyme. In other embodiments, a protein can be characterized as a UGT enzyme based on the presence of one or more domains in the protein that are associated with UGT enzymes. For example, in certain embodiments, a protein is characterized as a UGT enzyme based on the presence of a sugar binding domain and/or a catalytic domain,

characteristic of UGT enzymes known in the art. In certain embodiments, the catalytic domain binds the substrate to be glycosylated.

In other embodiments, a protein can be characterized as a UGT enzyme based on a comparison of the three-dimensional structure of the protein compared to the three-dimensional structure of a known UGT enzyme. For example, a protein could be characterized as a UGT based on the number or position of alpha helical domains, beta-sheet domains, etc. It should be appreciated that a UGT enzyme can be a synthetic protein.

In some embodiments, the UGT does not comprise the sequence of SEQ ID NO: 109. In some embodiments, a UGT comprises less than 95%, less than 94%, less than 93%, less than 92%, less than 91%, less than 90%, less than 89%, less than 88%, less than 87%, less than 86%, less than 85%, less than 84%, less than 83%, less than 82%, less than 81%, less than 80%, less than 79%, less than 78%, less than 77%, less than 76%, less than 75%, less than 74%, less than 73%, less than 72%, less than 71%, or less than 70% identity to SEQ ID NO: 109.

Cl 1 hydroxylase enzymes

Aspects of the present disclosure provide Cl 1 hydroxylase enzymes, which may be useful, for example, in the production of mogrol.

A Cl 1 hydroxylase of the present disclosure may comprise a sequence that is at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical, including all values in between, with a Cl l hydroxylase sequence ( e.g ., nucleic acid or amino acid sequence) in Table 8, with a sequence set forth as SEQ ID NOs: 113,

114, 129, or 130, or to any Cl l hydroxylase sequence disclosed in this application or known in the art.

In some embodiments, a Cl 1 hydroxylase of the present disclosure is capable of oxidizing mogrol precursors (e.g., cucurbitadienol, l l-hydroxycucurbitadienol, 24,25-dihydroxy- cucurbitadienol, and/or 24,25-epoxy-cucurbitadienol). In some embodiments, a Cl 1

hydroxylase of the present disclosure catalyzes the formation of mogrol.

It should be appreciated that activity, such as specific activity, of a Cl l hydroxylase can be determined by any means known to one of ordinary skill in the art. In some embodiments, activity (e.g., specific activity) of a Cl l hydroxylase may be measured as the concentration of a mogrol precursor produced or mogrol produced per unit of enzyme per unit time. In some embodiments, a Cl l hydroxylase of the present disclosure has an activity (e.g., specific activity) of at least 0.0001-0.001 pmol/min/mg, at least 0.001-0.01 pmol/min/mg, at least 0.01-0.1 pmol/min/mg, or at least 0.1-1 pmol/min/mg, including all values in between.

In some embodiments, the activity, such as specific activity, of a Cl l hydroxylase is at least 1.1 fold (e.g., at least 1.3 fold, at least 1.5 fold, at least 1.7 fold, at least 1.9 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, at least 100 fold, at least 1000 fold or at least 10000 fold, including all values in between) greater than that of a control Cl l hydroxylase.

Cytochrome P450 reductase enzymes

Aspects of the present disclosure provide cytochrome P450 reductase enzymes, which may be useful, for example, in the production of mogrol. Cytochrome P450 reductase is also referred to as NADPHTerrihemoprotein oxidoreductase, NADPH:hemoprotein oxidoreductase, NADPH:P450 oxidoreductase, P450 reductase, POR, CPR, and CYPOR. These reductases can promote Cl l hydroxylase activity by catalyzing electron transfer from NADPH to a Cl 1 hydroxylase.

Cytochrome P450 reductases of the present disclosure may comprise a sequence that is at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 71%, at least 72%, at least73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical, including all values in between, with a cytochrome P450 reductase sequence ( e.g ., nucleic acid or amino acid sequence) in Table 8, with a sequence set forth as SEQ ID NOs: 115, 116, 131, or 132, or to any cytochrome p450 reductase disclosed in this application or known in the art.

In some embodiments, a cytochrome P450 reductase of the present disclosure is capable of promoting oxidation of a mogrol precursor (e.g., cucurbitadienol, l l-hydroxycucurbitadienol, 24,25-dihydroxy-cucurbitadienol, and/or 24,25-epoxy-cucurbitadienol). In some embodiments, a P450 reductase of the present disclosure catalyzes the formation of a mogrol precursor or mogrol.

It should be appreciated that activity (e.g., specific activity) of a cytochrome P450 reductase can be measured by any means known to one of ordinary skill in the art. In some embodiments, activity (e.g., specific activity) of a recombinant cytochrome P450 reductase may be measured as the concentration of a mogrol precursor produced or mogrol produced per unit enzyme per unit time in the presence of a Cl 1 hydroxylase. In some embodiments, a cytochrome P450 reductase of the present disclosure has a activity (e.g., specific activity) of at least 0.0001- 0.001 pmol/min/mg, at least 0.001-0.01 pmol/min/mg, at least 0.01-0.1 pmol/min/mg, or at least 0.1-1 pmol/min/mg, including all values in between.

In some embodiments, the activity (e.g., specific activity) of a cytochrome P450 reductase is at least 1.1 fold (e.g., at least 1.3 fold, at least 1.5 fold, at least 1.7 fold, at least 1.9 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, at least 100 fold, at least 1000 fold or at least 10000 fold, including all values in between) greater than that of a control cytochrome P450 reductase.

Epoxide hydrolase enzymes ( EPHs )

Aspects of the present disclosure provide epoxide hydrolase enzymes (EPHs), which may be useful, for example, in the conversion of 24-25 epoxy-cucurbitadienol to 24-25 dihydroxy- cucurbitadienol or in the conversion of 11 -hydroxy-24, 25 -epoxycucurbitadienol to mogrol.

EPHs are capable of converting an epoxide into two hydroxyls.

EPHs of the present disclosure may comprise a sequence that is at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical, including all values in between, with a EPH sequence ( e.g ., nucleic acid or amino acid sequence) in Table 8, with a sequence set forth as SEQ ID NOs: 117-125 or 133-141, or to any EPH sequence disclosed in this application or known in the art.

In some embodiments, a recombinant EPH of the present disclosure is capable of promoting hydrolysis of an epoxide in a cucurbitadienol compound (e.g., hydrolysis of the epoxide in 24-25 epoxy-cucurbitadienol). In some embodiments, an EPH of the present disclosure catalyzes the formation of a mogrol precursor (e.g., 24-25 dihydroxy-cucurbitadienol).

It should be appreciated that activity (e.g., specific activity) of an EPH can be measured by any means known to one of ordinary skill in the art. In some embodiments, activity (e.g., specific activity) of an EPH may be measured as the concentration of a mogrol precursor (e.g., 24-25 dihydroxy-cucurbitadienol) or mogrol produced. In some embodiments, a recombinant EPH of the present disclosure will allow production of at least l-l00pg/L, at least 100- l000pg/L, at least l-lOOmg/L, at least lOO-lOOOmg/L, at least l-lOg/L or at least lO-lOOg/L, including all values in between.

In some embodiments, the activity (e.g., specific activity) of an EPH is at least 1.1 fold (e.g., at least 1.3 fold, at least 1.5 fold, at least 1.7 fold, at least 1.9 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, or at least 100 fold, including all values in between) greater than that of a control EPH.

Squalene epoxidases enzymes (SQEs) Aspects of the present disclosure provide squalene epoxidases (SQEs), which are capable of oxidizing a squalene ( e.g ., squalene or 2-3-oxidosqualene) to produce a squalene epoxide ( e.g ., 2-3-oxidosqualene or 2-3, 22-23-diepoxysqualene). SQEs may also be referred to as squalene monooxygenases.

SQEs of the present disclosure may comprise a sequence that is at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 71%, at least 72%, at least73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical, including all values in between, with a SQE sequence (e.g., nucleic acid or amino acid sequence) in Table 8, with a sequence set forth as SEQ ID NOs: 126-128 or 142-144, or to any SQE sequence disclosed in this application or known in the art.

In some embodiments, an SQE of the present disclosure is capable of promoting formation of an epoxide in a squalene compound (e.g., epoxidation of squalene or 2,3- oxidosqualene). In some embodiments, an SQE of the present disclosure catalyzes the formation of a mogrol precursor (e.g., 2-3-oxidosqualene or 2-3, 22-23-diepoxysqualene).

Activity, such as specific activity, of a recombinant SQE may be measured as the concentration of a mogrol precursor (e.g., 2-3-oxidosqualene or 2-3, 22-23-diepoxysqualene) produced per unit of enzyme per unit of time. In some embodiments, an SQE of the present disclosure has an activity, such as specific activity, of at least 0.0000001 pmol/min/mg (e.g., at least 0.000001 pmol/min/mg, at least 0.00001 pmol/min/mg, at least 0.0001 pmol/min/mg, at least 0.001 pmol/min/mg, at least 0.01 pmol/min/mg, at least 0.1 pmol/min/mg, at least 1 pmol/min/mg, at least 10 pmol/min/mg, or at least 100 pmol/min/mg, including all values in between).

In some embodiments, the activity, such as specific activity, of a SQE is at least 1.1 fold (e.g., at least 1.3 fold, at least 1.5 fold, at least 1.7 fold, at least 1.9 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, or at least 100 fold, including all values in between) greater than that of a control SQE. Variants

Aspects of the disclosure relate to polynucleotides encoding any of the recombinant polypeptides described, such as CDS, UGT, Cl l hydroxylase, cytochrome P450 reductase, and EPH, and SQE enzymes. Variants of polynucleotide or amino acid sequences described in this application are also encompassed by the present disclosure. A variant may share at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or

100% sequence identity with a reference sequence, including all values in between.

Unless otherwise noted, the term“sequence identity,” as known in the art, refers to a relationship between the sequences of two polypeptides or polynucleotides, as determined by sequence comparison (alignment). In some embodiments, sequence identity is determined across the entire length of a sequence, while in other embodiments, sequence identity is determined over a region of a sequence.

Identity can also refer to the degree of sequence relatedness between two sequences as determined by the number of matches between strings of two or more residues ( e.g ., nucleic acid or amino acid residues). Identity measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model, algorithms, or computer program.

Identity of related polypeptides or nucleic acid sequences can be readily calculated by any of the methods known to one of ordinary skill in the art. The“percent identity” of two sequences (e.g., nucleic acid or amino acid sequences) may, for example, be determined using the algorithm of Karlin and Altschul Proc. Natl. Acad. Sci. USA 87:2264-68, 1990, modified as in Karlin and Altschul Proc. Natl. Acad. Sci. USA 90:5873-77, 1993. Such an algorithm is incorporated into the NBLAST ^® and XBLAST ^® programs (version 2.0) of Altschul et ah, J. Mol. Biol. 215:403-10, 1990. BLAST ^® protein searches can be performed, for example, with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the protein molecules of the invention. Where gaps exist between two sequences, Gapped BLAST ^® can be utilized, for example, as described in Altschul et al, Nucleic Acids Res. 25(l7):3389- 3402, 1997. When utilizing BLAST ^® and Gapped BLAST ^® programs, the default parameters of the respective programs ( e.g ., XBLAST ^® and NBLAST ^® ) can be used, or the parameters can be adjusted appropriately as would be understood by one of ordinary skill in the art.

Another local alignment technique which may be used, for example, is based on the Smith- Waterman algorithm (Smith, T.F. & Waterman, M.S. (1981)“Identification of common molecular subsequences.” J. Mol. Biol. 147:195-197). A general global alignment technique which may be used, for example, is the Needleman-Wunsch algorithm (Needleman, S.B. & Wunsch, C.D. (1970)“A general method applicable to the search for similarities in the amino acid sequences of two proteins.” J. Mol. Biol. 48:443-453), which is based on dynamic programming.

More recently, a Fast Optimal Global Sequence Alignment Algorithm (FOGSAA) was developed that purportedly produces global alignment of nucleic acid and amino acid sequences faster than other optimal global alignment methods, including the Needleman-Wunsch algorithm. In some embodiments, the identity of two polypeptides is determined by aligning the two amino acid sequences, calculating the number of identical amino acids, and dividing by the length of one of the amino acid sequences. In some embodiments, the identity of two nucleic acids is determined by aligning the two nucleotide sequences and calculating the number of identical nucleotide and dividing by the length of one of the nucleic acids.

For multiple sequence alignments, computer programs including Clustal Omega (Sievers et al, Mol Syst Biol. 2011 Oct 11 ;7:539) may be used.

It should be appreciated that a sequence, including a nucleic acid or amino acid sequence, may be found to have a specified percent identity to a reference sequence, such as a sequence disclosed in this application and/or recited in the claims, using any method known to one of ordinary skill in the art. Different algorithms may yield different percent identity values for a given set of sequences. The claims of this application should be understood to encompass sequences for which percent identity to a reference sequence is calculated using default parameters and/or parameters typically used by the skilled artisan for a given algorithm.

As used in this application, a residue (such as a nucleic acid residue or an amino acid residue) in sequence“X” is referred to as corresponding to a position or residue (such as a nucleic acid residue or an amino acid residue)“z” in a different sequence“Y” when the residue in sequence“X” is at the counterpart position of“z” in sequence“Y” when sequences X and Y are aligned using amino acid sequence alignment tools known in the art.

Variant sequences may be homologous sequences. As used in this application, homologous sequences are sequences (e.g., nucleic acid or amino acid sequences) that share a certain percent identity (e.g., at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% percent identity, including all values in between). Homologous sequences include but are not limited to paralogous sequences, orthologous sequences, or sequences arising from convergent evolution. Paralogous sequences arise from duplication of a gene within a genome of a species, while orthologous sequences diverge after a speciation event. Two different species may have evolved independently but may each comprise a sequence that shares a certain percent identity with a sequence from the other species as a result of convergent evolution.

In some embodiments, a polypeptide variant (e.g., CDS, UGT, Cl l hydroxylase, cytochrome P450 reductase, EPH, or SQE variant) comprises a domain that shares a secondary structure (e.g., alpha helix, beta sheet) with a reference polypeptide (e.g., a reference CDS, ETGT, Cl l hydroxylase, cytochrome P450 reductase, EPH, or SQE). In some embodiments, a polypeptide variant (e.g., CDS, ETGT, Cl l hydroxylase, cytochrome P450 reductase, EPH, or SQE variant) shares a tertiary structure with a reference polypeptide (e.g., a reference CDS,

UGT, Cl l hydroxylase, cytochrome P450 reductase, EPH, or SQE). As a non-limiting example, a variant polypeptide may have low primary sequence identity (e.g., less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, or less than 5% sequence identity) compared to a reference polypeptide, but share one or more secondary structures (e.g., including but not limited to loops, alpha helices, or beta sheets, or have the same tertiary structure as a reference polypeptide. For example, a loop may be located between a beta sheet and an alpha helix, between two alpha helices, or between two beta sheets. Homology modeling may be used to compare two or more tertiary structures.

Mutations can be made in a nucleotide sequence by a variety of methods known to one of ordinary skill in the art. For example, mutations can be made by PCR-directed mutation, site- directed mutagenesis according to the method of Kunkel (Kunkel, Proc. Nat. Acad. Sci. U.S.A.

82: 488-492, 1985), by chemical synthesis of a gene encoding a polypeptide, by gene editing tools, or by insertions, such as insertion of a tag (e.g., a HIS tag or a GFP tag). Mutations can include, for example, substitutions, deletions, and translocations, generated by any method known in the art. Methods for producing mutations may be found in in references such as Molecular Cloning: A Laboratory Manual, J. Sambrook, et ah, eds., Fourth Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2012, or Current Protocols in

Molecular Biology, F.M. Ausubel, et ah, eds., John Wiley & Sons, Inc., New York, 2010.

In some embodiments, methods for producing variants include circular permutation (Yu and Lutz, Trends Biotechnol. 2011 Jan;29(l): 18-25). A non-limiting example of circular permutation is provided in Example 5 and FIG. 7. In circular permutation, the linear primary sequence of a polypeptide can be circularized (e.g., by joining the N-terminal and C-terminal ends of the sequence) and the polypeptide can be severed (“broken”) at a different location.

Thus, the linear primary sequence of the new polypeptide may have low sequence identity (e.g., less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less or less than 5%, including all values in between) as determined by linear sequence alignment methods (e.g., Clustal Omega or BLAST). Topological analysis of the two proteins, however, may reveal that the tertiary structure of the two

polypeptides is similar or dissimilar. Without being bound by a particular theory, a variant polypeptide created through circular permutation of a reference polypeptide and with a similar tertiary structure as the reference polypeptide can share similar functional characteristics (e.g., enzymatic activity, enzyme kinetics, substrate specificity or product specificity). In some instances, circular permutation may alter the secondary structure, tertiary structure or quaternary structure and produce an enzyme with different functional characteristics (e.g., increased or decreased enzymatic activity, different substrate specificity, or different product specificity).

See, e.g., Yu and Lutz, Trends Biotechnol. 2011 Jan;29(l): 18-25. It should be appreciated that in a protein that has undergone circular permutation, the linear amino acid sequence of the protein would differ from a reference protein that has not undergone circular permutation. However, one of ordinary skill in the art would be able to determine which residues in the protein that has undergone circular permutation correspond to residues in the reference protein that has not undergone circular permutation by, for example, aligning the sequences and detecting conserved motifs, and/or by comparing the structures or predicted structures of the proteins, e.g., by homology modeling.

In some embodiments, an algorithm that determines the percent identity between a sequence of interest and a reference sequence described in this application accounts for the presence of circular permutation between the sequences. The presence of circular permutation may be detected using any method known in the art, including, for example, RASPODOM (Weiner et ah, Bioinformatics. 2005 Apr l;2l(7):932-7). In some embodiments, the presence of circulation permutation is corrected for (e.g., the domains in at least one sequence are rearranged) prior to calculation of the percent identity between a sequence of interest and a sequence described in this application. The claims of this application should be understood to encompass sequences for which percent identity to a reference sequence is calculated after taking into account potential circular permutation of the sequence.

Functional variants of the recombinant CDSs, UGTs, Cl l hydroxylases, cytochrome P450 reductases, EPHs, and squalene epoxidases disclosed in this application are also encompassed by the present disclosure. For example, functional variants may bind one or more of the same substrates (e.g., mogrol, mogroside, or precursors thereof) or produce one or more of the same products (e.g., mogrol, mogroside, or precursors thereof). Functional variants may be identified using any method known in the art. For example, the algorithm of Karlin and Altschul Proc. Natl. Acad. Sci. USA 87:2264-68, 1990 described above may be used to identify homologous proteins with known functions.

Putative functional variants may also be identified by searching for polypeptides with functionally annotated domains. Databases including Pfam (Sonnhammer et al, Proteins. 1997 Jul;28(3):405-20) may be used to identify polypeptides with a particular domain. For example, among oxidosqualene cyclases, additional CDS enzymes may be identified in some instances by searching for polypeptides with a leucine residue corresponding to position 123 of SEQ ID NO: 74. This leucine residue has been implicated in determining the product specificity of the CDS enzyme; mutation of this residue can, for instance, result in cycloartenol or parked as a product (Takase et al, Org Biomol Chem. 2015 Jul l3(26):7331-6).

Additional UGT enzymes may be identified, for example, by searching for polypeptides with a UDPGT domain (PROSITE accession number PS00375).

Homology modeling may also be used to identify amino acid residues that are amenable to mutation without affecting function. A non-limiting example of such a method may include use of position- specific scoring matrix (PSSM) and an energy minimization protocol (see, e.g., Example 5 below). See, e.g. _^ Stormo et al, Nucleic Acids Res. 1982 May l l;l0(9):2997-30l l.

PSSM may be paired with calculation of a Rosetta energy function, which determines the difference between the wild-type and the single-point mutant. Without being bound by a particular theory, potentially stabilizing mutations are desirable for protein engineering (e.g., production of functional homologs). In some embodiments, a potentially stabilizing mutation has a AAG _ca/c value of less than -0.1 (e.g., less than -0.2, less than -0.3, less than -0.35, less than - 0.4, less than -0.45, less than -0.5, less than -0.55, less than -0.6, less than -0.65, less than -0.7, less than -0.75, less than -0.8, less than -0.85, less than -0.9, less than -0.95, or less than -1.0) Rosetta energy units (R.e.u.). See, e.g., Goldenzweig et al, Mol Cell. 2016 Jul 2l;63(2):337- 346. doi: l0.l0l6/j.molcel.20l6.06.0l2.

In some embodiments, a CDS, ETGT, Cl l hydroxylase, cytochrome P450 reductase,

EPH, or SQE coding sequence comprises a mutation at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,

41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66,

67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,

93, 94, 95, 96, 97, 98, 99, 100 or more than 100 positions corresponding to a reference coding sequence. In some embodiments, the CDS, ETGT, Cl l hydroxylase, cytochrome P450 reductase, EPH, or SQE coding sequence comprises a mutation in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,

15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,

41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66,

67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,

93, 94, 95, 96, 97, 98, 99,100 or more codons of the coding sequence relative to a reference coding sequence. As will be understood by one of ordinary skill in the art, a mutation within a codon may or may not change the amino acid that is encoded by the codon due to degeneracy of the genetic code. In some embodiments, the one or more mutations in the coding sequence do not alter the amino acid sequence of the coding sequence relative to the amino acid sequence of a reference polypeptide.

In some embodiments, the one or more mutations in a recombinant CDS, UGT, Cl 1 hydroxylase, cytochrome P450 reductase, EPH, or SQE sequence alter the amino acid sequence of the polypeptide relative to the amino acid sequence of a reference polypeptide. In some embodiments, the one or more mutations alter the amino acid sequence of the recombinant polypeptide relative to the amino acid sequence of a reference polypeptide and alter (enhance or reduce) an activity of the polypeptide relative to the reference polypeptide.

The activity, including specific activity, of any of the recombinant polypeptides described in this application may be measured using routine methods. As a non-limiting example, a recombinant polypeptide’s activity may be determined by measuring its substrate specificity, product(s) produced, the concentration of product(s) produced, or any combination thereof. As used in this application,“specific activity” of a recombinant polypeptide refers to the amount ( e.g ., concentration) of a particular product produced for a given amount (e.g., concentration) of the recombinant polypeptide per unit time.

The skilled artisan will also realize that mutations in a recombinant polypeptide coding sequence may result in conservative amino acid substitutions to provide functionally equivalent variants of the foregoing polypeptides, e.g., variants that retain the activities of the polypeptides. As used in this application, a“conservative amino acid substitution” refers to an amino acid substitution that does not alter the relative charge or size characteristics or functional activity of the protein in which the amino acid substitution is made.

In some instances, an amino acid is characterized by its R group (see, e.g., Table 1). For example, an amino acid may comprise a nonpolar aliphatic R group, a positively charged R group, a negatively charged R group, a nonpolar aromatic R group, or a polar uncharged R group. Non-limiting examples of an amino acid comprising a nonpolar aliphatic R group include alanine, glycine, valine, leucine, methionine, and isoleucine. Non-limiting examples of an amino acid comprising a positively charged R group includes lysine, arginine, and histidine. Non limiting examples of an amino acid comprising a negatively charged R group include aspartate and glutamate. Non-limiting examples of an amino acid comprising a nonpolar, aromatic R group include phenylalanine, tyrosine, and tryptophan. Non-limiting examples of an amino acid comprising a polar uncharged R group include serine, threonine, cysteine, proline, asparagine, and glutamine.

Non-limiting examples of functionally equivalent variants of polypeptides may include conservative amino acid substitutions in the amino acid sequences of proteins disclosed in this application. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D. Additional non-limiting examples of conservative amino acid substitutions are provided in Table 1.

In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more than 20 residues can be changed when preparing variant polypeptides. In some

embodiments, amino acids are replaced by conservative amino acid substitutions.

Table 1. Non-limiting Examples of conservative amino acid substitutions

Amino acid substitutions in the amino acid sequence of a polypeptide to produce a recombinant polypeptide variant having a desired property and/or activity can be made by alteration of the coding sequence of the polypeptide. Similarly, conservative amino acid substitutions in the amino acid sequence of a polypeptide to produce functionally equivalent variants of the polypeptide typically are made by alteration of the coding sequence of the recombinant polypeptide (e.g., UGT, CDS, P450, cytochrome P450 reductase, EPH, or squalene epoxidase).

Expression of Nucleic Acids in Host Cells

Aspects of the present disclosure relate to the recombinant expression of genes encoding enzymes, functional modifications and variants thereof, as well as uses relating thereto. For example, the methods described in this application may be used to produce mogrol precursors, mogrol and/or mogrosides.

The term“heterologous” with respect to a polynucleotide, such as a polynucleotide comprising a gene, is used interchangeably with the term“exogenous” and the term

“recombinant” and refers to: a polynucleotide that has been artificially supplied to a biological system; a polynucleotide that has been modified within a biological system; or a polynucleotide whose expression or regulation has been manipulated within a biological system. A

heterologous polynucleotide that is introduced into or expressed in a host cell may be a polynucleotide that comes from a different organism or species than the host cell, or may be a synthetic polynucleotide, or may be a polynucleotide that is also endogenously expressed in the same organism or species as the host cell. For example, a polynucleotide that is endogenously expressed in a host cell may be considered heterologous when it is: situated non-naturally in the host cell; expressed recombinantly in the host cell, either stably or transiently; modified within the host cell; selectively edited within the host cell; expressed in a copy number that differs from the naturally occurring copy number within the host cell; or expressed in a non-natural way within the host cell, such as by manipulating regulatory regions that control expression of the polynucleotide. In some embodiments, a heterologous polynucleotide is a polynucleotide that is endogenously expressed in a host cell but whose expression is driven by a promoter that does not naturally regulate expression of the polynucleotide. In other embodiments, a heterologous polynucleotide is a polynucleotide that is endogenously expressed in a host cell and whose expression is driven by a promoter that does naturally regulate expression of the polynucleotide, but the promoter or another regulatory region is modified. In some embodiments, the promoter is recombinantly activated or repressed. For example, gene-editing based techniques may be used to regulate expression of a polynucleotide, including an endogenous polynucleotide, from a promoter, including an endogenous promoter. See, e.g., Chavez el al, Nat Methods. 2016 Jul; 13(7): 563-567. A heterologous polynucleotide may comprise a wild-type sequence or a mutant sequence as compared with a reference polynucleotide sequence.

A nucleic acid encoding any of the recombinant polypeptides, such as CDSs, UGTs, Cl 1 hydroxylases, cytochrome P450 reductases, EPHs, or SQEs) described in this application may be incorporated into any appropriate vector through any method known in the art. For example, the vector may be an expression vector, including but not limited to a viral vector (e.g., a lentiviral, retroviral, adenoviral, or adeno-associated viral vector), any vector suitable for transient expression, any vector suitable for constitutive expression, or any vector suitable for inducible expression (e.g., a galactose-inducible or doxycyc line-inducible vector). A non-limiting example of a vector for expression of a recombinant polypeptide (e.g., CDS, UGT, Cl 1 hydroxylase, cytochrome P450 reductase, EPH, or squalene epoxidase) is described in Example 1 below.

In some embodiments, a vector replicates autonomously in the cell. A vector can contain one or more endonuclease restriction sites that are cut by a restriction endonuclease to insert and ligate a nucleic acid containing a gene described in this application to produce a recombinant vector that is able to replicate in a cell. Vectors are typically composed of DNA, although RNA vectors are also available. Cloning vectors include, but are not limited to: plasmids, fosmids, phagemids, virus genomes and artificial chromosomes. As used in this application, the terms "expression vector" or "expression construct" refer to a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell, such as a yeast cell. In some

embodiments, the nucleic acid sequence of a gene described in this application is inserted into a cloning vector such that it is operably joined to regulatory sequences and, in some embodiments, expressed as an RNA transcript. In some embodiments, the vector contains one or more markers, such as a selectable marker as described in this application, to identify cells transformed or transfected with the recombinant vector. In some embodiments, the nucleic acid sequence of a gene described in this application is re-coded. Re-coding may increase production of the gene product by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%, including all values in between) relative to a reference sequence that is not re-coded.

A coding sequence and a regulatory sequence are said to be“operably joined” or “operably linked” when the coding sequence and the regulatory sequence are covalently linked and the expression or transcription of the coding sequence is under the influence or control of the regulatory sequence. If the coding sequence is to be translated into a functional protein, the coding sequence and the regulatory sequence are said to be operably joined or linked if induction of a promoter in the 5’ regulatory sequence permits the coding sequence to be transcribed and if the nature of the linkage between the coding sequence and the regulatory sequence does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein.

In some embodiments, the nucleic acid encoding any of the proteins described in this application is under the control of regulatory sequences (e.g., enhancer sequences). In some embodiments, a nucleic acid is expressed under the control of a promoter. The promoter can be a native promoter, e.g., the promoter of the gene in its endogenous context, which provides normal regulation of expression of the gene. Alternatively, a promoter can be a promoter that is different from the native promoter of the gene, e.g., the promoter is different from the promoter of the gene in its endogenous context. As used in this application, a“heterologous promoter” or “recombinant promoter” is a promoter that is not naturally or normally associated with or that does not naturally or normally control transcription of a DNA sequence to which it is operably joined. In some embodiments, a nucleotide sequence is under the control of a heterologous promoter.

In some embodiments, the promoter is a eukaryotic promoter. Non-limiting examples of eukaryotic promoters include TDH3, PGK1, PKC1, PDC1, TEF1, TEF2, RPL18B, SSA1,

TDH2, RUKI,TRII GAL1, GAL 10, GAL7, GAL3, GAL2, MET3, MET25, HXT3, HXT7, ACT1, ADH1, ADH2, CETP1-1, EN02, and SOD1, as would be known to one of ordinary skill in the art (see, e.g., Addgene website: blog.addgene.org/plasmids-lOl-the-promoter-region). In some embodiments, the promoter is a prokaryotic promoter (e.g., bacteriophage or bacterial promoter). Non-limiting examples of bacteriophage promoters include Plslcon, T3, T7, SP6, and PL. Non-limiting examples of bacterial promoters include Pbad, PmgrB, Ptrc2, Plac/ara, Ptac, and Pm.

In some embodiments, the promoter is an inducible promoter. As used in this application, an“inducible promoter” is a promoter controlled by the presence or absence of a molecule. Non-limiting examples of inducible promoters include chemically-regulated promoters and physically-regulated promoters. For chemically-regulated promoters, the transcriptional activity can be regulated by one or more compounds, such as alcohol, tetracycline, galactose, a steroid, a metal, or other compounds. For physically-regulated promoters, transcriptional activity can be regulated by a phenomenon such as light or temperature. Non-limiting examples of tetracycline-regulated promoters include

anhydrotetracycline (aTc)-responsive promoters and other tetracycline-responsive promoter systems ( e.g ., a tetracycline repressor protein (tetR), a tetracycline operator sequence (tetO) and a tetracycline transactivator fusion protein (tTA)). Non-limiting examples of steroid-regulated promoters include promoters based on the rat glucocorticoid receptor, human estrogen receptor, moth ecdysone receptors, and promoters from the steroid/retinoid/thyroid receptor superfamily. Non-limiting examples of metal-regulated promoters include promoters derived from

metallothionein (proteins that bind and sequester metal ions) genes. Non-limiting examples of pathogenesis-regulated promoters include promoters induced by salicylic acid, ethylene or benzothiadiazole (BTH). Non-limiting examples of temperature/heat- inducible promoters include heat shock promoters. Non-limiting examples of light-regulated promoters include light responsive promoters from plant cells. In certain embodiments, the inducible promoter is a galactose-inducible promoter. In some embodiments, the inducible promoter is induced by one or more physiological conditions (e.g., pH, temperature, radiation, osmotic pressure, saline gradients, cell surface binding, or concentration of one or more extrinsic or intrinsic inducing agents). Non-limiting examples of an extrinsic inducer or inducing agent include amino acids and amino acid analogs, saccharides and polysaccharides, nucleic acids, protein transcriptional activators and repressors, cytokines, toxins, petroleum-based compounds, metal containing compounds, salts, ions, enzyme substrate analogs, hormones or any combination thereof.

In some embodiments, the promoter is a constitutive promoter. As used in this application, a“constitutive promoter” refers to an unregulated promoter that allows continuous transcription of a gene. Non-limiting examples of a constitutive promoter include TDH3, PGK1, PKC1, PDC1, TEF1, TEF2, RPL18B, SSA1, TDH2, RUKI,TRII, HXT3, HXT7, ACT1, ADH1, ADH2, EN02, and SOD 1.

Other inducible promoters or constitutive promoters known to one of ordinary skill in the art are also contemplated.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but generally include, as necessary, 5’ non-transcribed and 5’ non- translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. In particular, such 5’ non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences. The vectors disclosed in this application may include 5' leader or signal sequences. The regulatory sequence may also include a terminator sequence. In some embodiments, a terminator sequence marks the end of a gene in DNA during transcription. The choice and design of one or more appropriate vectors suitable for inducing expression of one or more genes described in this application in a host cell is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing the necessary elements for expression are commercially available and known to one of ordinary skill in the art (see, e.g., Sambrook et ah, Molecular Cloning: A Laboratory Manual, Fourth Edition, Cold Spring Harbor Laboratory Press, 2012).

In some embodiments, introduction of a polynucleotide, such as a polynucleotide encoding a recombinant polypeptide, into a host cell results in genomic integration of the polynucleotide. In some embodiments, a host cell comprises at least 1 copy, at least 2 copies, at least 3 copies, at least 4 copies, at least 5 copies, at least 6 copies, at least 7 copies, at least 8 copies, at least 9 copies, at least 10 copies, at least 11 copies, at least 12 copies, at least 13 copies, at least 14 copies, at least 15 copies, at least 16 copies, at least 17 copies, at least 18 copies, at least 19 copies, at least 20 copies, at least 21 copies, at least 22 copies, at least 23 copies, at least 24 copies, at least 25 copies, at least 26 copies, at least 27 copies, at least 28 copies, at least 29 copies, at least 30 copies, at least 31 copies, at least 32 copies, at least 33 copies, at least 34 copies, at least 35 copies, at least 36 copies, at least 37 copies, at least 38 copies, at least 39 copies, at least 40 copies, at least 41 copies, at least 42 copies, at least 43 copies, at least 44 copies, at least 45 copies, at least 46 copies, at least 47 copies, at least 48 copies, at least 49 copies, at least 50 copies, at least 60 copies, at least 70 copies, at least 80 copies, at least 90 copies, at least 100 copies, or more, including any values in between, of a polynucleotide sequence, such as a polynucleotide sequence encoding any of the recombinant polypeptides described in this application, in its genome.

Host Cells

Any of the proteins or enzymes of the disclosure may be expressed in a host cell. As used in this application, the term“host cell” refers to a cell that can be used to express a polynucleotide, such as a polynucleotide that encodes an enzyme used in production of mogrol, mogrosides, and precursors thereof.

Any suitable host cell may be used to produce any of the recombinant polypeptides, including CDSs, UGTs, Cl l hydroxylases, cytochrome P450 reductases, EPHs, and SQEs disclosed in this application, including eukaryotic cells or prokaryotic cells. Suitable host cells include, but are not limited to, fungal cells (e.g., yeast cells), bacterial cells (e.g., E. coli cells), algal cells, plant cells, insect cells, and animal cells, including mammalian cells.

Suitable yeast host cells include, but are not limited to, Candida, Escherichia, Hansenula, Saccharomyces (e.g., S. cerevisiae), Schizosaccharomyces, Pichia, Kluyveromyces (e.g., K.

lactis ), and Yarrowia. In some embodiments, the yeast cell is Hansenula polymorpha,

Saccharomyces cerevisiae, Saccaromyces carlsbergensis, Saccharomyces diastaticus,

Saccharomyces norbensis, Saccharomyces kluyveri, Schizosaccharomyces pombe, Pichia finlandica, Pichia trehalophila, Pichia kodamae, Pichia membranaefaciens, Pichia opuntiae, Pichia thermotolerans, Pichia salictaria, Pichia quercuum, Pichia pijperi, Pichia stipitis, Pichia methanolica, Pichia angusta, Kluyveromyces lactis, Candida albicans, or Yarrowia lipolytica.

In some embodiments, the yeast strain is an industrial polyploid yeast strain. Other non limiting examples of fungal cells include cells obtained from Aspergillus spp., Penicillium spp., Fusarium spp., Rhizopus spp., Acremonium spp., Neurospora spp., Sordaria spp., Magnaporthe spp ., Allomyces spp., Ustilago spp., Botrytis spp., and Trichoderma spp.

In certain embodiments, the host cell is an algal cell such as, Chlamydomonas (e.g., C. Reinhardtii) and Phormidium (P. sp. ATCC29409). In other embodiments, the host cell is a prokaryotic cell. Suitable prokaryotic cells include gram positive, gram negative, and gram-variable bacterial cells. The host cell may be a species of, but not limited to: Agrobacterium, Alicyclobacillus, Anabaena, Anacystis,

Acinetobacter, Acidothermus, Arthrobacter, Azobacter, Bacillus, Bifidobacterium,

Brevibacterium, Butyrivibrio, Buchnera, Campestris, Camplyobacter, Clostridium,

Corynebacterium, Chromatium, Coprococcus, Escherichia, Enterococcus, Enterobacter, Erwinia, Fusobacterium, Faecalibacterium, Francisella, Flavobacterium, Geobacillus,

Haemophilus, Helicobacter, Klebsiella, Lactobacillus, Lactococcus, Ilyobacter, Micrococcus, Microbacterium, Mesorhizobium, Methylobacterium, Methylobacterium, Mycobacterium, Neisseria, Pantoea, Pseudomonas, Prochlorococcus, Rhodobacter, Rhodopseudomonas, Rhodopseudomonas, Roseburia, Rhodospirillum, Rhodococcus, Scenedesmus, Streptomyces, Streptococcus, Synecoccus, Saccharomonospora, Saccharopolyspora, Staphylococcus, Serratia, Salmonella, Shigella, Thermoanaerobacterium, Tropheryma, Tularensis, Temecula,

Thermosynechococcus, Thermococcus, Ureaplasma, Xanthomonas, Xylella,

Yersinia, and Zymomonas.

In some embodiments, the bacterial host cell is of the Agrobacterium species (e.g., A. radiobacter, A. rhizogenes, A. rubi ), the Arlhrobacler species (e.g., A. aurescens, A. citreus, A. globformis, A. hydrocarboglutamicus, A. mysorens, A. nicotianae, A. paraffineus, A.

protophonniae, A. roseoparaffinus, A. sulfureus, A. ureafaciens ), or the Bacillus species (e.g., B. thuringiensis, B. anthracis, B. megaterium, B. subtilis, B. lentus, B. circulans, B. pumilus, B. lautus, B. coagulans, B. brevis, B. firmus, B. alkaophius, B. licheniformis, B. clausii, B.

stearothermophilus, B. halodurans and B. amyloliquefaciens . In particular embodiments, the host cell is an industrial Bacillus strain including but not limited to B. subtilis, B. pumilus, B. licheniformis, B. megaterium, B. clausii, B. stearothermophilus and B. amyloliquefaciens. In some embodiments, the host cell is an industrial Clostridium species (e.g., C. acetobutylicum, C. tetani E88, C. lituseburense, C. saccharobutylicum, C. perfringens, C. beijerinckii). In some embodiments, the host cell is an industrial Corynebacterium species (e.g., C. glutamicum, C. acetoacidophilum). In some embodiments, the host cell is an industrial Escherichia species (e.g., E. coli). In some embodiments, the host cell is an industrial Erwinia species (e.g., E.

uredovora, E. carotovora, E. ananas, E. herbicola, E. punctata, E. terreus). In some

embodiments, the host cell is an industrial Pantoea species (e.g., P. citrea, P. agglomerans). In some embodiments, the host cell is an industrial Pseudomonas species, ( e.g ., P. putida, P.

aeruginosa, P. mevalonii). In some embodiments, the host cell is an

industrial Streptococcus species (e.g., S. equisimiles, S. pyogenes, S. uberis). In some embodiments, the host cell is an industrial Streptomyces species (e.g., S. ambofaciens, S.

achromogenes, S. avermitilis, S. coelicolor, S. aureofaciens, S. aureus, S. fungicidicus, S.

griseus, S. Uvidans). In some embodiments, the host cell is an industrial Zymomonas species (e.g., Z. mobilis, Z. lipolytica).

The present disclosure is also suitable for use with a variety of animal cell types, including mammalian cells, for example, human (including 293, HeLa, WI38, PER.C6 and Bowes melanoma cells), mouse (including 3T3, NS0, NS1, Sp2/0), hamster (CHO, BHK), monkey (COS, FRhL, Vero), and hybridoma cell lines.

The present disclosure is also suitable for use with a variety of plant cell types.

The term“cell,” as used in this application, may refer to a single cell or a population of cells, such as a population of cells belonging to the same cell line or strain. Use of the singular term“cell” should not be construed to refer explicitly to a single cell rather than a population of cells.

The host cell may comprise genetic modifications relative to a wild-type counterpart. As a non-limiting example, a host cell (e.g., S. cerevisiae ) may be modified to reduce or inactivate one or more of the following genes: hydroxymethylglutaryl-CoA (HMG-CoA) reductase (HMG1), acetyl-CoA C-acetyltransferase (acetoacetyl-CoA thiolase) (ERG10), 3-hydroxy-3- methylglutaryl-CoA (HMG-CoA) synthase (ERG13), farnesyl-diphosphate farnesyl transferase (squalene synthase) (ERG9), may be modified to overexpress squalene epoxidase (ERG1), or may be modified to downregulate lanosterol synthase (ERG7). See, e.g., Examples 1 and 2 below.

Reduction of gene expression and/or gene inactivation may be achieved through any suitable method, including but not limited to deletion of the gene, introduction of a point mutation into the gene, truncation of the gene, introduction of an insertion into the gene, introduction of a tag or fusion into the gene, or selective editing of the gene. For example, polymerase chain reaction (PCR)-based methods may be used (see. _, e.g., Gardner el al, Methods Mol Biol. 2014;1205:45-78) or well-known gene-editing techniques may be used. As a non limiting example, genes may be deleted through gene replacement (e.g., with a marker, including a selection marker). A gene may also be truncated through the use of a transposon system (see, e.g., Poussu et al., Nucleic Acids Res. 2005; 33(12): el04).

A vector encoding any of the recombinant polypeptides described in this application may be introduced into a suitable host cell using any method known in the art. Non-limiting examples of yeast transformation protocols are described in Gietz et al, Yeast transformation can be conducted by the LiAc/SS Carrier DNA/PEG method. Methods Mol Biol. 2006;313:107- 20, which is incorporated by reference in its entirety. Host cells may be cultured under any suitable conditions as would be understood by one of ordinary skill in the art. For example, any media, temperature, and incubation conditions known in the art may be used. For host cells carrying an inducible vector, cells may be cultured with an appropriate inducible agent to promote expression.

Any of the cells disclosed in this application can be cultured in media of any type (rich or minimal) and any composition prior to, during, and/or after contact and/or integration of a nucleic acid. The conditions of the culture or culturing process can be optimized through routine experimentation as would be understood by one of ordinary skill in the art. In some

embodiments, the selected media is supplemented with various components. In some

embodiments, the concentration and amount of a supplemental component is optimized. In some embodiments, other aspects of the media and growth conditions (e.g., pH, temperature, etc.) are optimized through routine experimentation. In some embodiments, the frequency that the media is supplemented with one or more supplemental components, and the amount of time that the cell is cultured, is optimized.

Culturing of the cells described in this application can be performed in culture vessels known and used in the art. In some embodiments, an aerated reaction vessel (e.g., a stirred tank reactor) is used to culture the cells. In some embodiments, a bioreactor or fermentor is used to culture the cell. Thus, in some embodiments, the cells are used in fermentation. As used in this application, the terms“bioreactor” and“fermentor” are interchangeably used and refer to an enclosure, or partial enclosure, in which a biological, biochemical and/or chemical reaction takes place, involving a living organism, part of a living organism, or purified enzymes. A“large- scale bioreactor” or“industrial-scale bioreactor” is a bioreactor that is used to generate a product on a commercial or quasi-commercial scale. Farge scale bioreactors typically have volumes in the range of liters, hundreds of liters, thousands of liters, or more. Non-limiting examples of bioreactors include: stirred tank fermentors, bioreactors agitated by rotating mixing devices, chemostats, bioreactors agitated by shaking devices, airlift fermentors, packed-bed reactors, fixed-bed reactors, fluidized bed bioreactors, bioreactors employing wave induced agitation, centrifugal bioreactors, roller bottles, and hollow fiber bioreactors, roller apparatuses (for example benchtop, cart-mounted, and/or automated varieties), vertically- stacked plates, spinner flasks, stirring or rocking flasks, shaken multi-well plates, MD bottles, T-flasks, Roux bottles, multiple- surface tissue culture propagators, modified fermentors, and coated beads ( e.g ., beads coated with serum proteins, nitrocellulose, or carboxymethyl cellulose to prevent cell attachment).

In some embodiments, the bioreactor includes a cell culture system where the cell (e.g., yeast cell) is in contact with moving liquids and/or gas bubbles. In some embodiments, the cell or cell culture is grown in suspension. In other embodiments, the cell or cell culture is attached to a solid phase carrier. Non-limiting examples of a carrier system includes microcarriers (e.g., polymer spheres, microbeads, and microdisks that can be porous or non-porous), cross-linked beads (e.g., dextran) charged with specific chemical groups (e.g., tertiary amine groups), 2D microcarriers including cells trapped in nonporous polymer fibers, 3D carriers (e.g., carrier fibers, hollow fibers, multicartridge reactors, and semi-permeable membranes that can comprising porous fibers), microcarriers having reduced ion exchange capacity, encapsulation cells, capillaries, and aggregates. In some embodiments, carriers are fabricated from materials such as dextran, gelatin, glass, or cellulose.

In some embodiments, industrial-scale processes are operated in continuous, semi- continuous or non-continuous modes. Non-limiting examples of operation modes are batch, fed batch, extended batch, repetitive batch, draw/fill, rotating-wall, spinning flask, and/or perfusion mode of operation. In some embodiments, a bioreactor allows continuous or semi-continuous replenishment of the substrate stock, for example a carbohydrate source and/or continuous or semi-continuous separation of the product, from the bioreactor.

In some embodiments, the bioreactor or fermentor includes a sensor and/or a control system to measure and/or adjust reaction parameters. Non-limiting examples of reaction parameters include biological parameters (e.g., growth rate, cell size, cell number, cell density, cell type, or cell state, etc.), chemical parameters (e.g., pH, redox-potential, concentration of reaction substrate and/or product, concentration of dissolved gases, such as oxygen concentration and C0 ₂ concentration, nutrient concentrations, metabolite concentrations, concentration of an oligopeptide, concentration of an amino acid, concentration of a vitamin, concentration of a hormone, concentration of an additive, serum concentration, ionic strength, concentration of an ion, relative humidity, molarity, osmolarity, concentration of other chemicals, for example buffering agents, adjuvants, or reaction by-products), physical/mechanical parameters (e.g., density, conductivity, degree of agitation, pressure, and flow rate, shear stress, shear rate, viscosity, color, turbidity, light absorption, mixing rate, conversion rate, as well as

thermodynamic parameters, such as temperature, light intensity/quality, etc.). Sensors to measure the parameters described in this application are well known to one of ordinary skill in the relevant mechanical and electronic arts. Control systems to adjust the parameters in a bioreactor based on the inputs from a sensor described in this application are well known to one of ordinary skill in the art in bioreactor engineering.

In some embodiments, the method involves batch fermentation (e.g., shake flask fermentation). General considerations for batch fermentation (e.g., shake flask fermentation) include the level of oxygen and glucose. For example, batch fermentation (e.g., shake flask fermentation) may be oxygen and glucose limited, so in some embodiments, the capability of a strain to perform in a well-designed fed-batch fermentation is underestimated. Also, the final product (e.g., mogrol precursor, mogrol, mogroside precursor, or mogroside) may display some differences from the substrate (e.g., mogrol precursor, mogrol, mogroside precursor, or mogroside) in terms of solubility, toxicity, cellular accumulation and secretion and in some embodiments can have different fermentation kinetics.

The methods described in this application encompass production of the mogrol precursors (e.g., squalene, 2,3-oxidosqualene, or 24-25 epoxy-cucurbitadienol), mogrol, or mogrosides (e.g., MIA1, MIE1, MIIA1, MIIA2, MIIIA1, MIIE, Mill, siamenoside I, mogroside IV, isomogroside IV, MIIIE, and mogroside V) using a recombinant cell, cell lysate or isolated recombinant polypeptides (e.g., CDS, UGT, Cl l hydroxylase, cytochrome P450 reductase, EPH, and squalene epoxidase).

Mogrol precursors (e.g., squalene, 2,3-oxidosqualene, or 24-25 epoxy-cucurbitadienol), mogrol, mogrosides (e.g., MIA1, MIE, MIIA1, MIIA2, MIIIA1, MIIE, Mill, siamenoside I, mogroside IV, isomogroside IV, MIIIE, and mogroside V) produced by any of the recombinant cells disclosed in this application may be identified and extracted using any method known in the art. Mass spectrometry ( e.g ., LC-MS, GC-MS) is a non-limiting example of a method for identification and may be used to help extract of a compound of interest.

The phraseology and terminology used in this application is for the purpose of description and should not be regarded as limiting. The use of terms such as“including,” “comprising,”“having,”“containing,”“involving, ” and/or variations thereof in this application, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

EXAMPLES

Example 1. Identification and Functional Characterization of CDS enzymes

A library of putative CDS enzymes was designed. The library included some

oxidosqualene cyclase sequences that were modified to be more similar to CDSs.

Product made by a control strain expressing the S. grosvenorii CDS was identified as cucurbitadienol by NMR, and it was confirmed that hydroxylations of this product led to the production of mogrol. The putative CDS enzymes were evaluated to identify active enzyme(s) that catalyze cyclization of 2,3-oxidosqualene to cucurbitadienol. A total of 506 constructs from the putative CDS library were tested by transforming the library into an engineered S. cerevisiae screening strain. The S. cerevisiae screening strain comprised: a truncated HMG1 gene;

overexpression of the ERG10, ERG13, ERG9, and ERG1 genes; and downregulation of the ERG7 gene. Genes encoding putative CDSs were expressed on a pESC-ETRA plasmid and expression was induced by culturing in SC-URA with 4% galactose. Cucurbitadienol was measured using GC-MS.

Forty CDSs were demonstrated to exhibit activity in the screen (Table 2). These CDSs included previously unidentified CDSs, as well as engineered CDSs. Some of the newly discovered enzymes showed as much as 2X or higher production of cucurbitadienol compared to the production of cucurbitadienol from a control strain that expressed a previously characterized CDS (SEQ ID NO: 73) from S. grosvenorii. SEQ ID NO: 33 is a non-limiting example of a polynucleotide sequence encoding SEQ ID NO: 73.

Therefore, various enzymes that can cyclize 2,3-oxidosqualene to cucurbitadienol have been identified and characterized.

Table 2. Cucurbitadienol Production by Putative CDS Enzymes.

It was concluded that the identified enzymes produced cucurbitadienol. GC-MS spectra of the product made by the newly discovered enzymes were very similar to cucurbitadienol produced with S. grosvenorii CDS in S. cerevisiae. This conclusion was confirmed with GC-MS, LC-MS and NMR. Cucurbitadienol made from these enzymes had a retention time, ionization pattern, and mass and fragmentation pattern identical to the cucurbitadienol made from the S. grosvenorii CDS.

Example 2. Identification and Functional Characterization of Putative UGT enzymes

This Example describes the design and screening of a UGT library to identify UGTs capable of converting mogrol and mogroside precursors into glycosylated mogrosides.

Specifically, the library aimed to identify UGTs that glycosylate at the C3 and C24 hydroxyl groups of mogrol to yield mogrosides with different glucose units. A total of 1,059 putative UGTs were obtained.

To test the UGT library, an in vitro assay was developed. Plasmids carrying UGTs were transformed into S. cerevisiae CEN.PK D GAL80. The UGT library was screened in this assay using a total of 8 substrates: mogrol, mogroside I-Al, mogroside I-El, mogroside II-A1, mogroside II-E, mogroside III, mogroside III-A1, and mogroside III-E. The cell lysates were incubated with 50mM of substrate at 30°C for 24 hours before being quenched. Product formation was tested by LC-MS after quenching the reactions. LC-MS profiles for mogrol and mogroside standards are shown in FIG. 2.

Based on this screen, UGTs were identified that could produce known mogroside products, including mogroside I-Al and siamenoside I (FIGs. 3A-3B). Strains identified from this screen were then tested in an additional screen (FIGs. 4A-4B, Table 3).

Table 3. Product Formation by Putative UGTs

Example 3. Further Characterization of UGTs

13 of the 16 UGTs identified from the screens described in Example 2 were expressed recombinantly in E.coli and purified using a 6xHis tag. Protein concentrations of these purified UGTs were determined by Bradford assay. The specific activities of the 13 UGTs were determined by incubating 50 mM of each substrate with the UGTs for 5 min at 30°C. Reactions were quenched and product concentrations quantified by LC-MS (FIG 4). Specific activities were calculated by dividing product concentration by the enzyme concentration and reaction time. The measured specific activities ranged from 0.01 to 5.53 mmol product / (g UGT * hr), with an average of 1.14.

Example 4. Protein Engineering of UGT94-289-1

The S. cerevisiae strain t85024 (expressing a recoded polynucleotide encoding UGT94- 289-1) was observed to catalyze the 6-1 & 2-1 glycosylation reactions. However, this enzyme did not catalyze these reactions at a high rate.

A library of UGT sequences was designed in which each UGT sequence contained a single amino acid substitution relative to the UGT94-289-1 sequence. The library of UGT sequences was tested for enhanced activity of the 6-1 & 2-1 glycosylations. The library contained 893 members. The positions to mutate were chosen either based on their proximity (within 4.5 angstrom) to the catalytic dyad (His ²¹ /Asp ¹²² ) or based on their predicted interactions with the substrate molecules. A homology model of UGT94-289-1 is shown in FIG. 5.

The 218 mutations that improved activity over the wild-type enzyme (UGT94-289-1) were identified through an in vitro screen (Table 4). Plasmids carrying the mutated UGT94-289- 1 genes were transformed into S. cerevisiae CEN.PK A GAL80. To test the UGT mutation library, the in vitro assay from Example 2 was performed. A total of 3 substrates - mogroside II- Al, mogroside III and mogroside II-E - were tested with the UGT mutation library using this assay.

A number of mutations were identified that enhanced the activity of these glycosylation steps (Table 4). In Table 4, MIIA1 indicates mogroside II-A1, MIIE indicates mogroside II-E, MIIIA1 indicates mogroside III-A1, Mill indicates mogroside III, MIIIE indicates mogroside III- E, and Siam indicates siamenoside I. A subset of the UGTs containing mutations identified (N143V, N143I, L374N, L374Y, and L374W) were expressed and purified in E. coli. N143V, N143I, & L374N were found to enhance the specific activities for the reactions of mogroside II- Al to mogroside III-A1 and mogroside III to siamenoside I by 4-8x and 12-16c, respectively, above the wild-type protein. L374Y and L374W were found to enhance the specific activity for the mogroside II-E to mogroside III-E reactions by 13c and 28x, respectively, above wild-type. These observations generally match the data observed in the S. cerevisiae screen (Table 4). Additionally, the N143V mutation was observed to produce mogroside V from siamenoside I, which is an activity not observed in the wild-type UGT or the other mutants.

Non-limiting examples of structural motifs in UGT94-289-1 and the sequences of the structural motifs are shown in Table 5.

Table 4. UGT94-289-1 Substitution Mutations

Table 5. Non-limiting Examples of Structural Motifs in UGT94-289-1 (SEQ ID NO: 109)

Example 5. Identification and Characterization of Additional UGTs

This Example describes further engineering of a UGT enzyme and identification of additional UGT enzymes.

Engineering of a UGT involved circular permutation of the protein sequence. The predicted structure of a representative UGT, UGT94-289-1 (FIG. 5) shows that the N and C termini are flexible and in close proximity (7-10 A, FIG. 6). To circularly permute, the original N and C termini were fused together and new termini were introduced at another position within the protein structure (FIG. 7).

Two libraries were screened. One contained circularly permutated versions of a UGT sequence. The other contained additional putative UGT sequences. The S. cerevisiae strain used for the screening comprised: a CDS, two EPHs, a mutant Cl l-hydroxylase fusion protein, two cytochrome P450 reductases, an upregulated SQE, two primary UGTs, and two transporter knockouts. Two different biological replicates of the same strain were used for screening. The biological replicates are referred to as Background 1 and Background 2. Plasmids encoding the UGTs were transformed into the screening strain. The transformants were inoculated into preculture medium and an aliquot of the inoculated medium was subsequently transferred to production plates.

Following incubation of the production plates, mogroside production was evaluated using a thermo QQQ TSQ-Quantiva ESI with a LX4 multiplexed columns setup. The masses for select ion monitoring (SIM) for the classes of glycosylations with the mogrol backbone (M, MI, Mil, Mill, MIV, MV) were as follows: 535.4 g/mol (M), 697.47 g/mol (MI), 799.51 g/mol (Mil), 961.56 g/mol (Mill), 1123.61 g/mol (MIV), and 1285.68 g/mol (MV) respectively. MI indicates a product with one glucose moiety, Mil indicates a product with two glucose moieties, Mill indicates a product with three glucose moieties, MIV indicates a product with four glucose moieties, and MV indicates a product with five glucose moieties. MI and Mil were considered substrates of a secondary UGT, whereas Mill, MIV, and MV were considered products of a secondary UGT. These selective ion monitoring (SIM) intensities were then normalized to an internal standard and calibrated against the following surrogates: MIA1, MIIA1, MIIIA1, Siamenoside, and MV. UGT94-289-1 N143I was used as a positive control. The negative control strain did not express a secondary UGT.

The percentages of MI, Mil, Mill, MIV, and MV produced by strains carrying each UGT were compared to the positive control strain. The fraction of MI, Mil, Mill, MIV, and MV corresponds to the amount of each type out of the total amount of product produced.

Enzymes were designated as having UGT activity (a hit) based on the following criteria. For the circularly permutated UGT library, enzymes were considered hits if they produced a fraction of MIV (MIV fraction) greater than the mean fraction of MIV (two standard deviations of MIV fraction of each positive control strain). This cutoff was used to identify structural variants that have improved folding and stability, which could have a trade-off with activity. Only constructs that were positive in both biological replicates were considered hits. Table 6 provides data for the MIV and MV fractions.

For the library of putative UGTs, enzymes were considered hits for each product (Mill, MIV, and MV) if they were two standard deviations above the maximum observed value of the negative control strain and greater than the mean of the positive control strain. Table 7 provides data for the Mill, MIV, and MV fractions.

Table 6. UGTs Generated by Circular Permutation

Table 7. Additional Putative UGTs

Example 6: Further Protein Engineering of UGTs

This Example describes further engineering of a UGT enzyme. A UGT mutation library was constructed based on a position-specific scoring matrix (PSSM) and energy minimization protocol (Goldenzweig et ah, Mol Cell. 2016 Jul 2l;63(2):337-346). In this approach, close homologs of a UGT were identified by a BLAST search. These homologs were aligned and a position- specific scoring matrix (PSSM) was calculated from the multiple sequence alignment (FIG. 8). Positions that feature greater sequence variability, such as positions 53 and 57 in FIG. 8, were positions chosen to mutate. The pool of potential amino acid changes was selected from those observed in the PSSM. For example, position 52 was mutated to either L, I, M, or V since these are amino acids observed in the PSSM at that position (FIG. 8). To reduce the mutant pool further, the impact of all potential substitutions on protein stability was evaluated using Rosetta. A pool of mutations used to construct the library comprised those substitutions observed within the PSSM that significantly enhance stability at highly variable positions (Goldenzweig et al., Mol Cell. 2016 Jul 2l;63(2):337-346.). The library will be screened to identify enzymes with UGT activity. Example 7: Expressing a Combination of Heterologous Enzymes to Produce a Mogrol Precursor, Mogrol, or a Mogroside

The recombinant proteins of the present disclosure are used in combination to produce a mogrol precursor, ( e.g ., 2-3-oxidosqualene, 2,3,22,23-dioxidosqualene, cucurbitadienol, 24, 25- expoxycucurbitadienol, 24,25-dihydroxycucurbitadienol), mogrol, or mogrosides (e.g., mogroside I-Al (MIA1), mogroside I-E (MIE), mogroside II-A1 (MIIA1), mogroside III-A1 (MIIIA1), mogroside II-E (MIIE), mogroside III (Mill), siamenoside I, mogroside IV, mogroside III-E (MIIIE), mogroside V, and mogroside VI).

For example, to produce mogrol, genes encoding enzymes such as a squalene epoxidase, a CDS, an epoxide hydrolase and a cytochrome P450 were expressed in host cells. In some instances, a cytochrome P450 reductase is also expressed in the yeast cells. Non-limiting examples of suitable squalene epoxidases, epoxide hydrolases, Cl l hydroxylases and

cytochrome P450 reductases are provided in Table 8 below. Non-limiting examples of CDSs are provided in Table 2. Mogrol is quantified using LC-MS. UGTs are further expressed in the host cells to produce mogrosides.

Alternatively, the recombinant proteins are purified from host cells and the mogrol is produced outside of the host cells. The recombinant proteins are added either sequentially or simultaneously to a reaction buffer comprising squalene.

Table 8. Non-Limiting Examples of Cll Hydroxylases (P450s), Cytochrome P450

Reductases, Epoxide Hydrolases (EPHs), and Squalene Epoxidases.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described in this application. Such equivalents are intended to be encompassed by the following claims.

All references, including patent documents, disclosed in this application are incorporated by reference in their entirety, particularly for the disclosure referenced in this application.